

GUIDELINES

References

- 1 Dykewicz CA, Jaffe HW, Kaplan JE, Spira TJ, Edlin BR, Chen RT *et al.* Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *MMWR Recomm Rep* 2000; **49**(RR-10): 1–125, CE1-7.
- 2 Centers for Disease Control and Prevention (CDC). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR* 1999; **48**(RR-10): 1–66.
- 3 CIBMTR Summary Slides. http://www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides/index.html.
- 4 Bachanova V, Brunstein CG, Burns LJ, Miller JS, Luo X, DeFor T *et al.* Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. *Bone Marrow Transplant* 2009; **43**: 237–244.
- 5 Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. *Transpl Infect Dis* 2004; **6**: 171–178.
- 6 Junghans C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG *et al.* Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. *Blood* 2002; **99**: 1978–1985.
- 7 Junghans C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG *et al.* Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. *Biol Blood Marrow Transplant* 2002; **8**: 512–520.
- 8 Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. *Leukemia* 2006; **20**: 1690–1700.
- 9 Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R *et al.* Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. *Bone Marrow Transplant* 1996; **18**: 767–776.
- 10 Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. *Annu Rev Immunol* 2007; **25**: 139–170.
- 11 Gaziev J, Lucarelli G. Stem cell transplantation and gene therapy for hemoglobinopathies. *Curr Hematol Rep* 2005; **4**: 126–131.
- 12 Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI *et al.* Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. *N Engl J Med* 2001; **344**: 881–888.
- 13 Giralt S. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date. *Clin Lymphoma Myeloma* 2007; **7**(Suppl 3): S102–S104.
- 14 Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y *et al.* The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. *Biol Blood Marrow Transplant* 2007; **13**: 1–25.
- 15 Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J *et al.* Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. *Leukemia* 2007; **21**: 12–17.
- 16 de Witte T, Suci S, Brand R, Muus P, Kroger N. Autologous stem cell transplantation in myelodysplastic syndromes. *Semin Hematol* 2007; **44**: 274–277.
- 17 Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. *Br J Haematol* 2007; **136**: 549–564.
- 18 Aschan J. Risk assessment in haematopoietic stem cell transplantation: conditioning. *Best Pract Res Clin Haematol* 2007; **20**: 295–310.
- 19 Leather HL, Wingard JR. Infections following hematopoietic stem cell transplantation. *Infect Dis Clin North Am* 2001; **15**: 483–520.
- 20 Fraser CJ, Scott Baker K. The management and outcome of chronic graft-versus-host disease. *Br J Haematol* 2007; **138**: 131–145.
- 21 Chaidos A, Kanfer E, Apperley JF. Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. *Best Pract Res Clin Haematol* 2007; **20**: 125–154.
- 22 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F *et al.* Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood* 2006; **108**: 1809–1820.
- 23 Urbano-Ispizua A. Risk assessment in haematopoietic stem cell transplantation: stem cell source. *Best Pract Res Clin Haematol* 2007; **20**: 265–280.
- 24 Petersdorf EW. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. *Best Pract Res Clin Haematol* 2007; **20**: 155–170.
- 25 Bjorkstrand B, Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. *Semin Hematol* 2007; **44**: 227–233.
- 26 Passweg J, Tyndall A. Autologous stem cell transplantation in autoimmune diseases. *Semin Hematol* 2007; **44**: 278–285.
- 27 Sadelain M, Rivella S, Lisowski L, Samakoglu S, Riviere I. Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. *Best Pract Res Clin Haematol* 2004; **17**: 517–534.
- 28 Leather HL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. *Blood Rev* 2006; **20**: 267–287.
- 29 Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. *Clin Infect Dis* 2001; **33**: 947–953.
- 30 Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J *et al.* Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. *Lancet* 2000; **355**: 1231–1237.
- 31 Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C *et al.* Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. *Blood* 2002; **100**: 1611–1618.
- 32 Baron F, Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. *Curr Opin Hematol* 2007; **14**: 145–151.
- 33 Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. *Blood* 2004; **103**: 767–776.
- 34 Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T *et al.* NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. *Blood Cells Mol Dis* 2008; **40**: 84–90.
- 35 Dazzi F, Fozza C. Disease relapse after hematopoietic stem cell transplantation: risk factors and treatment. *Best Pract Res Clin Haematol* 2007; **20**: 311–327.
- 36 Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G *et al.* Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. *Ann Oncol* 2006; **17**: 1134–1140.
- 37 Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A *et al.* Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. *Lancet* 2007; **369**: 1947–1954.
- 38 Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. *Curr Opin Immunol* 2006; **18**: 565–570.
- 39 Buckley RH, Schiff SE, Schiff RI, Roberts JL, Markert ML, Peters W *et al.* Haploidentical bone marrow stem cell transplantation in human

- severe combined immunodeficiency. *Semin Hematol* 1993; **30**(Suppl 4): 92–101; discussion 102–104.
- 40 Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F *et al.* Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. *N Engl J Med* 1998; **339**: 1186–1193.
 - 41 Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. *Bone Marrow Transplant* 2008; **41**: 473–481.
 - 42 Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA *et al.* Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. *Blood* 2001; **97**: 3380–3389.
 - 43 Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD *et al.* Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. *Blood* 2006; **108**: 4288–4290.
 - 44 Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K *et al.* Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. *Bone Marrow Transplant* 2007; **40**: 19–27.
 - 45 Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J *et al.* Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. *Oncology (Williston Park)* 2003; **17**: 94–100; discussion 103–107.
 - 46 Georges GE, Storb R. Review of 'minitransplantation': nonmyeloablative allogeneic hematopoietic stem cell transplantation. *Int J Hematol* 2003; **77**: 3–14.
 - 47 Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. *Curr Opin Oncol* 2001; **13**: 95–100.
 - 48 Giral S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C *et al.* Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. *Blood* 2001; **97**: 631–637.
 - 49 Hows JM, Passweg JR, Tichelli A, Locasciulli A, Szydlo R, Bacigalupo A *et al.* Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. *Bone Marrow Transplant* 2006; **38**: 799–805.
 - 50 Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MR *et al.* Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. *Blood* 2002; **100**: 2235–2242.
 - 51 Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. *Blood* 1990; **76**: 1647–1656.
 - 52 Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. *Blood* 2001; **98**: 489–491.
 - 53 Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. *Nature* 1997; **388**: 133–134.
 - 54 Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM *et al.* Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. *Blood* 1997; **89**: 3700–3707.
 - 55 Roux E, Dumont-Girard F, Starobinski M, Siegrist CA, Helg C, Chapuis B *et al.* Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. *Blood* 2000; **96**: 2299–2303.
 - 56 Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. *Am J Hematol* 1997; **54**: 131–138.
 - 57 Berger M, Figari O, Bruno B, Raiola A, Dominiotto A, Fiorone M *et al.* Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. *Bone Marrow Transplant* 2008; **41**: 55–62.
 - 58 Talmadge JE. Lymphocyte subset recovery following allogeneic bone marrow transplantation: CD4(+) cell count and transplant-related mortality. *Bone Marrow Transplant* 2008; **41**: 19–21.
 - 59 Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid helper T-cell recovery above 200 × 10⁶/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. *Bone Marrow Transplant* 2006; **37**: 1119–1128.
 - 60 Dumont-Girard F, Roux E, van Lier RA, Hale G, Helg C, Chapuis B *et al.* Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. *Blood* 1998; **92**: 4464–4471.
 - 61 Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM *et al.* Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. *N Engl J Med* 1995; **332**: 143–149.
 - 62 Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. *Biol Blood Marrow Transplant* 1995; **1**: 18–23.
 - 63 Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. *Transplantation* 2002; **73**: 1154–1158.
 - 64 Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kastensportes C *et al.* Age-dependent incidence, time course, and consequences of thymic renewal in adults. *J Clin Invest* 2005; **115**: 930–939.
 - 65 Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. *Blood* 2002; **99**: 872–878.
 - 66 Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I *et al.* Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. *Blood* 2007; **110**: 4543–4551.
 - 67 Thomson BG, Robertson KA, Gowan D, Heilman D, Broxmeyer HE, Emanuel D *et al.* Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. *Blood* 2000; **96**: 2703–2711.
 - 68 Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A *et al.* Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. *Blood* 2002; **99**: 2726–2733.
 - 69 Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A *et al.* Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. *Blood* 1995; **86**: 3979–3986.
 - 70 Sullivan KM, Mori M, Sanders J, Siadak M, Witherspoon RP, Anasetti C *et al.* Late complications of allogeneic and autologous marrow transplantation. *Bone Marrow Transplant* 1992; **10**(Suppl 1): 127–134.
 - 71 Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP *et al.* Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. *Blood* 1982; **60**: 714–720.
 - 72 Hakim FT, Mackall CL. The immune system: effector and target of GVHD. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). *Graft-vs-Host Disease*. Marcel Dekker: New York, 1997, pp 257–289.
 - 73 Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M *et al.* Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. *Exp Hematol* 2003; **31**: 941–952.
 - 74 van Burik JA, Brunstein CG. Infectious complications following unrelated cord blood transplantation. *Vox Sang* 2007; **92**: 289–296.
 - 75 Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J *et al.* Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. *Blood* 2001; **97**: 1232–1240.
 - 76 AABB. *Standards for Cellular Therapy Product Services*, 2nd edn. AABB: Bethesda, MD, 2007.
 - 77 FACT-JACIE. *International Standards for Cellular Therapy Product Collection, Processing, and Administration*, 3rd edn. Foundation for the Accreditation of Cellular Therapy: Omaha, 2006.
 - 78 National Marrow Donor Program. *National Marrow Donor Program Standards*, 19th edn. National Marrow Donor Program: Minneapolis, 2004.
 - 79 World Marrow Donor Association. *International Standards for Unrelated Hematopoietic Stem Cell Donor Registries*. World Marrow Donor Association: Leiden, The Netherlands, 2007.
 - 80 Food and Drug Administration. *Guidance for Industry: Eligibility Determination for Donors Of Human Cells, Tissues, and Cellular- and Tissue-Based Products (HCT/TPs)*. US Department of Health and Human Services: Washington, DC, 2007.

References

- 81 European Commission. Commission Directive 2004/23/EC. *Official Journal of the European Union* 2004, L 10248–L 10258.
- 82 European Commission. Commission Directive 2006/17/EC. *Official Journal of the European Union* 2006, L 3840–L 3852.
- 83 US National Archives and Records Administration. *21 CFR, Part 1271, Subpart C—Donor Eligibility*. GPO: Washington, DC, 2004.
- 84 Centers for Disease Control and Prevention. West Nile virus transmission through blood transfusion—South Dakota, 2006. *MMWR Morb Mortal Wkly Rep* 2007; **56**: 76–79.
- 85 Centers for Disease Control and Prevention. West Nile virus update—United States, January 1–November 13, 2007. *MMWR Morb Mortal Wkly Rep* 2007; **56**: 1191–1192.
- 86 Centers for Disease Control and Prevention. West Nile virus infections in organ transplant recipients—New York and Pennsylvania, August–September, 2005. *MMWR Morb Mortal Wkly Rep* 2005; **54**: 1021–1023.
- 87 Centers for Disease Control and Prevention. Transfusion-associated transmission of West Nile virus—Arizona, 2004. *MMWR Morb Mortal Wkly Rep* 2004; **53**: 842–844.
- 88 Centers for Disease Control and Prevention. Detection of West Nile virus in blood donations—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 769–772.
- 89 Centers for Disease Control and Prevention. Update: detection of West Nile virus in blood donations—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 916–919.
- 90 Centers for Disease Control and Prevention. Investigation of blood transfusion recipients with West Nile virus infections. *MMWR Morb Mortal Wkly Rep* 2002; **51**: 823.
- 91 Food and Drug Administration. Suitability determination for donors of human cellular and tissue-based products: proposed rule. *Fed Regist* 1999; **64**: 52696–52723.
- 92 Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. *Vox Sang* 2006; **91**: 221–230.
- 93 Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. *Br J Haematol* 2006; **132**: 13–24.
- 94 Hart J, Leier B, Nahiriak S. Informed consent for blood transfusion: should the possibility of prion risk be included? *Transfus Med Rev* 2004; **18**: 177–183.
- 95 Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J *et al*. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet* 2004; **363**: 417–421.
- 96 Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J *et al*. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. *Haematologica* 2006; **91**: 78–83.
- 97 Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. *J Infect Dis* 2002; **185**: 273–282.
- 98 Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y *et al*. Toxoplasmosis encephalitis following severe graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: 17 years experience in Fukuoka BMT group. *Eur J Haematol* 2007; **79**: 317–321.
- 99 Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2007; **44**: 857–866.
- 100 Slavin MA, Meyers JD, Remington JS, Hackman RC. *Toxoplasma gondii* infection in marrow transplant recipients: a 20 year experience. *Bone Marrow Transplant* 1994; **13**: 549–557.
- 101 Kitchen A, Mijovic A, Hewitt P. Transfusion-transmitted malaria: current donor selection guidelines are not sufficient. *Vox Sang* 2005; **88**: 200–201.
- 102 Kitchen AD, Barbara JA, Hewitt PE. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. *Vox Sang* 2005; **89**: 77–80.
- 103 Centers for Disease Control and Prevention. Probable transfusion-transmitted malaria—Houston, Texas, 2003. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 1075–1076.
- 104 Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. *New Engl J Med* 2001; **344**: 1973–1978.
- 105 Centers for Disease Control and Prevention. Transfusion-transmitted malaria—Missouri and Pennsylvania, 1996–1998. *MMWR Morb Mortal Wkly Rep* 1999; **48**: 253–256.
- 106 Villeneuve L, Cassaing S, Magnaval JF, Boisseau M, Huynh A, Demur C *et al*. Plasmodium falciparum infection following allogeneic bone-marrow transplantation. *Ann Trop Med Parasitol* 1999; **93**: 533–535.
- 107 O'Donnell J, Goldman JM, Wagner K, Ehinger G, Martin N, Leahy M *et al*. Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. *Bone Marrow Transplant* 1998; **21**: 313–314.
- 108 Lefrere F, Besson C, Datry A, Chaibi P, Leblond V, Binet JL *et al*. Transmission of Plasmodium falciparum by allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1996; **18**: 473–474.
- 109 Herwaldt BL, Neitzel DF, Gorlin JB, Jensen KA, Perry EH, Peglow WR *et al*. Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6-month period. *Transfusion* 2002; **42**: 1154–1158.
- 110 Kain KC, Jassoum SB, Fong IW, Hannach B. Transfusion-transmitted babesiosis in Ontario: first reported case in Canada. *CMAJ* 2001; **164**: 1721–1723.
- 111 Kjemtrup AM, Lee B, Fritz CL, Evans C, Chervenak M, Conrad PA. Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California. *Transfusion* 2002; **42**: 1482–1487.
- 112 Linden JV, Wong SJ, Chu FK, Schmidt GB, Bianco C. Transfusion-associated transmission of babesiosis in New York state. *Transfusion* 2000; **40**: 285–289.
- 113 Pantanowitz L, Telford SR, Cannon ME. Tick-borne diseases in transfusion medicine. *Transfus Med Rev* 2002; **12**: 85–106.
- 114 Pantanowitz L, Telford SR, Cannon ME. The impact of babesiosis on transfusion medicine. *Transfus Med Rev* 2002; **16**: 131–143.
- 115 AABB. *Standards for Blood Banks and Transfusion Services*, 25th edn. AABB: Bethesda, Maryland, 2008.
- 116 Klein MB, Miller JS, Nelson CM, Goodman JL. Primary bone marrow progenitors of both granulocytic and monocytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis. *J Infect Dis* 1997; **176**: 1405–1409.
- 117 Centers for Disease Control and Prevention. Blood donor screening for chagas disease—United States, 2006–2007. *MMWR Morb Mortal Wkly Rep* 2007; **56**: 141–143.
- 118 Centers for Disease Control and Prevention. Chagas disease after organ transplantation—Los Angeles, California, 2006. *MMWR Morb Mortal Wkly Rep* 2006; **55**: 798–800.
- 119 Centers for Disease Control and Prevention. Chagas disease after organ transplantation—United States, 2001. *MMWR Morb Mortal Wkly Rep* 2002; **51**: 210–212.
- 120 Leiby DA, Lenas BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with *Trypanosoma cruzi* infection transmitted by transfusion. *N Engl J Med* 1999; **341**: 1237–1239.
- 121 Leiby DA, Read EJ, Lenas BA, Yund AJ, Stumpf RJ, Kirchhoff LV *et al*. Seroepidemiology of *Trypanosoma cruzi*, etiologic agent of Chagas' disease, in US blood donors. *J Infect Dis* 1997; **176**: 1047–1052.
- 122 Dodd RY. Transmission of parasites by blood transfusion. *Vox Sang* 1998; **74**(Suppl): 2161–2163.
- 123 Aljurf M, Gyger M, Alrajhi A, Sahovic E, Chaudhri N, Musa M *et al*. Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. *Bone Marrow Transplant* 1999; **24**: 551–554.
- 124 Tavil B, Gulhan B, Ozcelik U, Cetin M, Tezcan I, Tuncer M *et al*. Tuberculin skin test positivity in pediatric allogeneic BMT recipients and donors in Turkey. *Pediatr Transplant* 2007; **11**: 414–418.
- 125 National Marrow Donor Program. *Donor Health History Screening Questionnaire*. National Marrow Donor Program: Minneapolis, 2007.
- 126 Husebekk A, Skaug K, Kolstad A, Dahl IM, Gutteberg T, Skogen B. Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products. *Transfusion* 2004; **44**: 942–943.
- 127 Reich-Slotky R, Semidei-Pomales M, Schwartz J. Microbial pathogens of hematopoietic stem cells—screening and testing for infectious diseases. *Rev Med Microbiol* 2007; **18**: 17–27.
- 128 Padley DJ, Dietz AB, Gastineau DA. Sterility testing of hematopoietic progenitor cell products: a single-institution series of culture-positive

- rates and successful infusion of culture-positive products. *Transfusion* 2007; **47**: 636–643.
- 129 Majado MJ, Garcia-Hernandez A, Morales A, Gonzalez C, Martinez-Sanchez V, Menasalvas A *et al*. Influence of harvest bacterial contamination on autologous peripheral blood progenitor cells post-transplant. *Xenotransplantation* 2007; **39**: 121–125.
 - 130 Khuu HM, Patel N, Carter CS, Murray PR, Read EJ. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method. *Transfusion* 2006; **46**: 2071–2082.
 - 131 Klein MA, Kadidlo D, McCullough J, McKenna DH, Burns LJ. Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae. *Biol Blood Marrow Transplant* 2006; **12**: 1142–1149.
 - 132 Kelly M, Roy DC, Labbe AC, Laverdiere M. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria? *Rev Med Microbiol* 2006; **38**: 183–188.
 - 133 Kamble R, Pant S, Selby GB, Kharfan-Dabaja MA, Sethi S, Kratochvil K *et al*. Microbial contamination of hematopoietic progenitor cell grafts—incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. *Transfusion* 2005; **45**: 874–878.
 - 134 Larrea L, de la Rubia J, Soler MA, Ribas P, Fernandez JM, Picon I *et al*. Quality control of bacterial contamination in autologous peripheral blood stem cells for transplantation. *Haematologica* 2004; **89**: 1232–1237.
 - 135 Khuu HM, Stock F, McGann M, Carter CS, Atkins JW, Murray PR *et al*. Comparison of automated culture systems with a CFR/USP-compliant method for sterility testing of cell-therapy products. *Cytotherapy* 2004; **6**: 183–195.
 - 136 Lowder JN, Whelton P. Microbial contamination of cellular products for hematolymphoid transplantation therapy: assessment of the problem and strategies to minimize the clinical impact. *Cytotherapy* 2003; **5**: 377–390.
 - 137 Padley DJ, Greiner CW, Heddlesten-Rediskel TL, Hopkins MK, Maasi ML, Gastineau DA. Endogenous microbial contamination of cultured autologous preparations in trials of cancer immunotherapy. *Cytotherapy* 2003; **5**: 147–152.
 - 138 Honohan A, Olthuis H, Bernards AT, van Beckhoven JM, Brand A. Microbial contamination of cord blood stem cells. *Vox Sang* 2002; **82**: 32–38.
 - 139 Gee AP. Product release assays. *Cytotherapy* 1999; **1**: 485–491.
 - 140 Gagnon JA, Porter K, Guerin D, Gluck S. Bacterial decontamination of blood stem cell apheresis products. *J Clin Apher* 1998; **13**: 103–107.
 - 141 Espinosa MTF, Fox R, Creger RJ, Lazarus HM. Microbiologic contamination of peripheral blood progenitor cells collected for hematopoietic cell transplantation. *Transfusion* 1996; **36**: 789–793.
 - 142 US National Archives and Records Administration. *21 CFR, Part 1271, Subpart D—Good Tissue Practice*. GPO: Washington, DC, 2004.
 - 143 NetCord-FACT. *International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection, and Release*, 3rd edn. Foundation for the Accreditation of Cellular Therapy: Omaha, 2006.
 - 144 Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. *Am J Infect Control* 2007; **35**(Suppl 2): S65–S164.
 - 145 Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T *et al*. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; **34**: 730.
 - 146 Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. *Ann Intern Med* 2005; **142**: 979–995.
 - 147 van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. *Eur J Cancer* 2005; **41**: 1372–1382.
 - 148 Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. *Eur J Cancer* 2007; **5**(Suppl 5): 5–12.
 - 149 Bucaneve G, Micozzi A, Menichetti F. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *N Engl J Med* 2005; **353**: 977–987.
 - 150 Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A *et al*. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. *Clin Infect Dis* 1996; **23**: 795–805.
 - 151 Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. *J Clin Oncol* 2003; **21**: 4127–4137.
 - 152 Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. *J Clin Oncol* 1998; **16**: 1179–1187.
 - 153 The European Antimicrobial Resistance Surveillance System (EARSS) Annual Report 2006. 2006 (20 February 2008).
 - 154 MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in *Staphylococcus aureus* and *Escherichia coli* in 17 US hospitals. *Clin Infect Dis* 2005; **41**: 435–440.
 - 155 Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini M. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. *Biomed Pharmacother* 2005; **59**: 511–516.
 - 156 Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). *Diagn Microbiol Infect Dis* 2006; **56**: 75–82.
 - 157 Blahova J, Kralikova K, Krcmery VS, Babalova M, Menkyna R, Glosova L *et al*. Four years of monitoring antibiotic resistance in microorganisms from bacteremic patients. *J Chemother* 2007; **19**: 665–669.
 - 158 Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis* 2006; **6**: 629–640.
 - 159 Oktem IM, Gulay Z, Bicmen M, Gur D, HITIT Project Study Group. qnrA prevalence in extended-spectrum beta-lactamase-positive *Enterobacteriaceae* isolates from Turkey. *Jpn J Infect Dis* 2008; **6**: 113–117.
 - 160 Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? *Clin Microbiol Infect* 2008; **14**: 295–297.
 - 161 Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S *et al*. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005; **353**: 2442–2449.
 - 162 Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. *J Clin Oncol* 1995; **13**: 1023–1035.
 - 163 Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP *et al*. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. *J Clin Oncol* 1997; **15**: 660–666.
 - 164 Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. *J Clin Oncol* 2006; **24**: 5207–5215.
 - 165 Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. *Ann Intern Med* 2007; **147**: 400–411.
 - 166 Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. *Blood* 1999; **93**: 3267–3275.
 - 167 Rand KJ, Houck H, Ganju A, Babington RG, Elfenein GJ. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. *Bone Marrow Transplant* 1989; **4**: 679–683.
 - 168 Bosi A, De Majo E, Guidi S, Parri F, Saccardi R, Vannucchi AM *et al*. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. *Haematologica* 1990; **75**: 109–112.
 - 169 Buckley RH, Schiff RI. Use of intravenous immune globulin in immunodeficiency diseases. *N Engl J Med* 1991; **325**: 110–117.
 - 170 Bowden RA, Myers JD. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS (eds). *Clinical Approach*

- to *Infection in the Compromised Host*, 3rd edn. Plenum Medical Book Co.: New York, NY, 1994, pp 601–628.
- 171 Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M *et al.* A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. *Biol Blood Marrow Transplant* 1996; **2**: 44–53.
 - 172 Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA *et al.* High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. *Ann Intern Med* 1993; **118**: 937–942.
 - 173 Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R *et al.* Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. *Transpl Infect Dis* 2008; **10**: 252–259.
 - 174 Aksu G, Ruhi MZ, Akan H, Bengisun S, Ustun C, Arslan O *et al.* Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. *Bone Marrow Transplant* 2001; **27**: 201–205.
 - 175 Kim DH, Bae NY, Sung WJ, Kim JG, Kim SW, Sohn SK *et al.* Hickman catheter site infections after allogeneic stem cell transplantation: single-center experience. *Transplant Proc* 2004; **36**: 3203–3207.
 - 176 Adler A, Yaniv I, Solter E, Freud E, Samra Z, Stein J *et al.* Catheter-associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. *J Pediatr Hematol Oncol* 2006; **28**: 23–28.
 - 177 Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Brusio PA *et al.* Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. *Infect Control Hosp Epidemiol* 1994; **15**(Part 1): 231–238.
 - 178 Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S *et al.* An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med* 2006; **355**: 2725–2732.
 - 179 Hanna H, Benjamin R, Chatziniakolaou I, Alakech B, Richardson D, Mansfield P *et al.* Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. *J Clin Oncol* 2004; **22**: 3163–3171.
 - 180 Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall Jr MJ, Metzler MH *et al.* Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. *Ann Surg* 2005; **242**: 193–200.
 - 181 Chatziniakolaou I, Hanna H, Graviss L, Chaiban G, Perego C, Arbuckle R *et al.* Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. *Infect Control Hosp Epidemiol* 2003; **24**: 961–963.
 - 182 O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG *et al.* Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002; **51**(RR-10): 1–29.
 - 183 Gillies D, O'Riordan L, Carr D, Frost J, Gunning R, O'Brien I. Gauze and tape and transparent polyurethane dressings for central venous catheters. *Cochrane Database Syst Rev* 2003, CD003827.
 - 184 Ruschulte H, Franke M, Gastmeier P, Zenz S, Mahr KH, Buchholz S *et al.* Prevention of central venous catheter related infections with chlorhexidine gluconate impregnated wound dressings: a randomized controlled trial. *Ann Hematol* 2009; **88**: 267–272.
 - 185 Timsit JF, Schwebel C, Bouadma L, Geoffroy A, Garrouste-Orgeas M, Pease S *et al.* Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. *JAMA* 2009; **301**: 1231–1241.
 - 186 Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. *Clin Infect Dis* 2006; **43**: 474–484.
 - 187 Raad I, Buzaid A, Rhyne J, Hachem R, Darouiche R, Safar H *et al.* Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. *Clin Infect Dis* 1997; **25**: 149–151.
 - 188 Chatziniakolaou I, Zipf TF, Hanna H, Umphrey J, Roberts WM, Sherertz R *et al.* Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. *Clin Infect Dis* 2003; **36**: 116–119.
 - 189 Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-tauridine-containing lock solution. *Nephrol Dial Transplant* 2004; **19**: 1546–1551.
 - 190 Broom J, Woods M, Allworth A, McCarthy J, Faoagali J, Macdonald S *et al.* Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial. *Scand J Infect Dis* 2008; **40**: 399–406.
 - 191 Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. *Mayo Clin Proc* 2006; **81**: 1159–1171.
 - 192 American Academy of Pediatrics/Committee on Infectious Diseases. Pneumococcal infections. In: Pickering LK (ed). *2006 Red Book: Report of the Committee on Infectious Diseases*, 27th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 525–537.
 - 193 Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R *et al.* Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. *Br J Haematol* 2002; **117**: 444–450.
 - 194 Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J *et al.* Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. *Clin Infect Dis* 2007; **44**: 625–634.
 - 195 Cordonnier C, Labopin M, Chesnel V, Ribaud P, Da La Camara R, Martino R *et al.* Influence of immunisation timing on the response to conjugate-pneumococcal vaccine after allogeneic stem cell transplant: final results of the EBMT IDWP01 Trial. *Bone Marrow Transplantation* 2008; **45**(Suppl 1): S2.
 - 196 Tauro S, Dobie D, Richardson G, Hastings M, Mahendra P. Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma. *Bone Marrow Transplant* 2000; **26**: 1017–1019.
 - 197 Perez Retortillo JA, Marco F, Richard C, Conde E, Manjon R, Bureo E *et al.* Pneumococcal pericarditis with cardiac tamponade in a patient with chronic graft-versus-host disease. *Bone Marrow Transplant* 1998; **21**: 299–300.
 - 198 Haddad PA, Repka TL, Weisdorf DJ. Penicillin-resistant *Streptococcus pneumoniae* septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature. *Am J Med* 2002; **113**: 152–155.
 - 199 Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among *Streptococcus pneumoniae* isolated in the USA: update from PROTEKT US Years 1–4. *Ann Clin Microbiol Antimicrob* 2008; **7**: 1.
 - 200 Goldman KE. Dental management of patients with bone marrow and solid organ transplantation. *Dent Clin North Am* 2006; **50**: 659–676, viii.
 - 201 Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 832–838.
 - 202 Alcaide F, Linares J, Pallares R, Carratala J, Benitez MA, Gudiol F *et al.* *In vitro* activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. *Antimicrob Agents Chemother* 1995; **39**: 2243–2247.
 - 203 Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P *et al.* Viridans streptococcal shock in bone marrow transplantation patients. *Am J Hematol* 1993; **42**: 354–358.
 - 204 American Academy of Pediatrics. *Haemophilus influenzae* infections. In: LK Pickering (ed). *2006 Red Book: Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 310–318.
 - 205 Barra A, Cordonnier C, Preziosi MP, Intrator L, Hessel L, Fritzell B *et al.* Immunogenicity of *Haemophilus influenzae* type b conjugate vaccine in allogeneic bone marrow recipients. *J Infect Dis* 1992; **166**: 1021–1028.
 - 206 Sable CA, Donowitz GA. Infections in bone marrow transplant recipients. *Clin Infect Dis* 1994; **18**: 273–284.
 - 207 Suzuki N, Mizue N, Hori T, Hatakeyama N, Kudoh T, Tsutsumi H. Pertussis in adolescence after unrelated cord blood transplantation. *Bone Marrow Transplant* 2003; **32**: 967.

- 208 American Academy of Pediatrics/Committee on Infectious Diseases. Pertussis. In: Pickering LK (ed). *2006 Red Book: Report of the Committee on Infectious Diseases*. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 502.
- 209 Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. *Blood* 2003; **101**: 4195–4200.
- 210 Ljungman P, Larsson K, Kumlien G, Aschan J, Barkholt L, Gustafsson-Jernberg A *et al*. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. *Scand J Infect Dis* 2002; **34**: 347–350.
- 211 Bowden R, Cays M, Schoch G, Sayers M, Slichter S, Welk K *et al*. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. *Blood* 1995; **86**: 3598–3603.
- 212 Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. *Transfus Med Rev* 2001; **15**: 1–20.
- 213 Ratko TA, Cummings JP, Oberman HA, Crookston KP, DeChristopher PJ, Eastlund DT *et al*. Evidence-based recommendations for the use of WBC-reduced cellular blood components. *Transfusion* 2001; **41**: 1310–1319.
- 214 Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. *Ann Intern Med* 1993; **118**: 173–178.
- 215 Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM *et al*. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. *Lancet* 1994; **343**: 749–753.
- 216 Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A *et al*. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. *Blood* 2002; **99**: 3050–3056.
- 217 Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. *Blood* 1996; **88**: 4063–4071.
- 218 Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC *et al*. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. *Ann Intern Med* 1993; **118**: 179–184.
- 219 Fries BC, Riddell SR, Kim HW, Corey L, Dahlgren C, Woolfrey A *et al*. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. *Biol Blood Marrow Transplant* 2005; **11**: 136–148.
- 220 Takami A, Mochizuki K, Asakura H, Yamazaki H, Okumura H, Nakao S. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. *Haematologica* 2005; **90**: 1290–1292.
- 221 Matsumura T, Narimatsu H, Kami M, Yuji K, Kusumi E, Hori A *et al*. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. *Biol Blood Marrow Transplant* 2007; **13**: 577–583.
- 222 Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. *J Infect Dis* 1996; **174**: 907–912.
- 223 Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. *Clin Microbiol Rev* 1998; **11**: 533–554.
- 224 Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. *Curr Opin Infect Dis* 2007; **20**: 408–411.
- 225 Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S *et al*. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving haematopoietic stem cell transplantation as compared to qualitative pp65-antigenemia. *Blood* 2007; **110**: 2757–2760.
- 226 Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M *et al*. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. *Blood* 2003; **101**: 5053–5060.
- 227 Mendez JC, Sia IG, Paya CV. Human cytomegalovirus. In: Lennette EH, (ed). *Laboratory Diagnosis of Viral Infections*, 3rd edn. Marcel Dekker, Inc.: New York, NY, 1999, pp 361–372.
- 228 Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF *et al*. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. *N Engl J Med* 1991; **325**: 1601–1607.
- 229 Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. *N Engl J Med* 1991; **324**: 1005–1011.
- 230 Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D *et al*. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2002; **99**: 1159–1164.
- 231 Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C *et al*. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006; **37**: 851–856.
- 232 Einsele H, Reusser P, Bornhauser M, Kalhs P, Ehninger G, Hebart H *et al*. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. *Blood* 2006; **107**: 3002–3008.
- 233 van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. *Bone Marrow Transplant* 2006; **37**: 693–698.
- 234 Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G *et al*. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. *Transpl Infect Dis* 2007; **9**: 102–107.
- 235 Volin L, Barkholt L, Nihtinen A, Aschan J, Uotinen H, Hägglund H *et al*. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation [abstract]. *Bone Marrow Transplant* 2008; **41**(Suppl 1): 47.
- 236 Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F *et al*. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. *Bone Marrow Transplant* 1998; **22**: 175–180.
- 237 Boeckh M, Hoy C, Torok-Storb B. Occult cytomegalovirus infection of marrow stroma. *Clin Infect Dis* 1998; **26**: 209–210.
- 238 Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M *et al*. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. *Blood* 2001; **97**: 867–874.
- 239 Gerna G, Lilleri D, Zecca M, Alessandrino EP, Baldanti F, Revello MG *et al*. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. *Haematologica* 2005; **90**: 526–533.
- 240 Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B *et al*. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. *Blood* 2000; **96**: 3286–3289.
- 241 Cesaro S, Zhou X, Manzardo C, Buonfrate D, Cusinato R, Tridello G *et al*. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. *J Clin Virol* 2005; **34**: 129–132.
- 242 Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U *et al*. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. *Transplantation* 2001; **71**: 880–885.
- 243 Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H *et al*. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Blood* 2001; **97**: 388–392.

- 244 Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. *Rev Med Virol* 2008; **18**: 233–246.
- 245 Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S *et al*. Increased incidence of cytomegalovirus disease after autologous CD34+ selected peripheral blood stem cell transplantation. *Blood* 1999; **94**: 4029–4035.
- 246 Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. *J Infect Dis* 1995; **172**: 939–943.
- 247 Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS *et al*. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. *Br J Haematol* 2000; **111**: 782–790.
- 248 Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. *Bone Marrow Transplant* 1997; **19**: 1111–1116.
- 249 Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD *et al*. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. *Bone Marrow Transplant* 1998; **21**: 597–605.
- 250 Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, ter Veer A, Li X, Niland JC *et al*. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. *J Infect Dis* 1997; **176**: 782–785.
- 251 Ljungman P, Aschan J, Azinge JN, Brandt L, Ehrnst A, Hammarstrom V *et al*. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. *Br J Haematol* 1993; **83**: 118–124.
- 252 Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED *et al*. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N Engl J Med* 1995; **333**: 1038–1044.
- 253 Cobbold M, Khan N, Pourghesari B, Tauro S, McDonald D, Osman H *et al*. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. *J Exp Med* 2005; **202**: 379–386.
- 254 Peggs KS, Verfuert S, Pizzey A, Khan N, Guiver M, Moss PA *et al*. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. *Lancet* 2003; **362**: 1375–1377.
- 255 Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J *et al*. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. *Blood* 2002; **99**: 3916–3922.
- 256 Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. *Immunol Lett* 1996; **52**: 145–152.
- 257 Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR *et al*. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. *Blood* 1988; **71**: 1234–1243.
- 258 Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED *et al*. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. *Blood* 1988; **72**: 520–529.
- 259 Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ *et al*. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. *Bone Marrow Transplant* 1996; **18**: 377–382.
- 260 Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA *et al*. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. *Blood* 1998; **91**: 3654–3661.
- 261 Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalanis T, Ljungman P *et al*. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. *Blood* 2000; **95**: 807–814.
- 262 van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenchel R, Thijssen SF *et al*. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. *Blood* 2001; **98**: 972–978.
- 263 Meerbach A, Wutzler P, Hafer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. *J Med Virol* 2008; **80**: 441–454.
- 264 Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH *et al*. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. *N Engl J Med* 1994; **330**: 1185–1191.
- 265 Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y *et al*. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. *Blood* 1998; **92**: 1549–1555.
- 266 Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. *J Clin Apher* 1999; **14**: 154–156.
- 267 Lucas KG, Sun Q, Burton RL, Tilden A, Vaughan WP, Carabasi M *et al*. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. *Hum Gene Ther* 2000; **11**: 1453–1463.
- 268 Cavazzana-Calvo M, Bensoussan D, Jabado N, Haddad E, Yvon E, Moskwa M *et al*. Prevention of EBV-induced B-lymphoproliferative disorder by *ex vivo* marrow B-cell depletion in HLA-phenotypical or non-identical T-depleted bone marrow transplantation. *Br J Haematol* 1998; **103**: 543–551.
- 269 Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. *N Engl J Med* 1981; **305**: 63–67.
- 270 Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M *et al*. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. *Lancet* 1983; **2**: 706–708.
- 271 Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. *Ann Intern Med* 1982; **96**: 265–269.
- 272 Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. *Ann Intern Med* 1984; **100**: 823–828.
- 273 Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis due to herpes simplex virus in marrow-transplant recipients. *Clin Infect Dis* 1992; **14**: 38–45.
- 274 Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on Herpes simplex virus (HSV) disease and drug-resistant HSV disease. *J Infect Dis* 2007; **196**: 266–270.
- 275 Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. A new nucleoside analog, 9-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, highly active *in vitro* against herpes simplex virus types 1 and 2. *Antimicrob Agents Chemother* 1982; **22**: 55–61.
- 276 Langston AA, Redei I, Caliendo AM, Somani J, Hutcherson D, Lonial S *et al*. Development of drug-resistant Herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. *Blood* 2002; **99**: 1085–1088.
- 277 Nichols WG, Boeckh M, Carter RA, Wald A, Corey L. Transferred Herpes simplex virus immunity after stem-cell transplantation: clinical implications. *J Infect Dis* 2003; **187**: 801–808.
- 278 Dignani MC, Mykietiak A, Michelet M, Intile D, Mammana L, Desmery P *et al*. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. *Bone Marrow Transplant* 2002; **29**: 263–267.
- 279 Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. *Bone Marrow Transplant* 2003; **31**: 51–55.
- 280 Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME *et al*. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. *Blood* 2007; **110**: 3071–3077.
- 281 Dekker CL, Prober CG. Pediatric uses of valacyclovir, penciclovir and famciclovir. *Pediatr Infect Dis J* 2001; **20**: 1079–1081.

- 282 Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2007; **56**(RR-4): 1–40.
- 283 Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. *J Infect Dis* 1988; **158**: 238–241.
- 284 Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA *et al*. The safety profile of varicella vaccine: a 10-year review. *J Infect Dis* 2008; **197**(Suppl 2): S165–S169.
- 285 Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD *et al*. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med* 2005; **352**: 2271–2284.
- 286 Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. *MMWR Morb Mortal Wkly Rep* 2006; **55**: 209–210.
- 287 Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. *Blood* 2006; **107**: 1800–1805.
- 288 Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose acyclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. *Bone Marrow Transplant* 2005; **35**: 1065–1069.
- 289 Hatchette T, Tipples GA, Peters G, Alsuwaidi A, Zhou J, Mailman TL. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. *Pediatr Infect Dis J* 2008; **27**: 75–77.
- 290 Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J *et al*. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. *Ann Intern Med* 1991; **115**: 19–21.
- 291 Weinstock DM, Boeckh M, Sepkowitz KA. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant* 2006; **12**: 1096–1097.
- 292 Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. *Herpes* 2006; **13**: 60–65.
- 293 Adler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. *Infect Control Hosp Epidemiol* 2008; **29**: 866–870.
- 294 Merck Varivax: Varicella Vaccine Live 2008.
- 295 Merck Zostavax: Zoster Vaccine Live 2007.
- 296 Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K *et al*. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. *N Engl J Med* 2002; **347**: 26–34.
- 297 Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J *et al*. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. *Infect Control Hosp Epidemiol* 1997; **18**: 412–416.
- 298 Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. *Am J Med* 1997; **102**(3A): 48–52; discussion 53–54.
- 299 Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections in transplant patients. *Infect Dis Clin North Am* 1995; **9**: 987–1003.
- 300 Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I *et al*. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. *Clin Infect Dis* 1996; **22**: 778–782.
- 301 Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM *et al*. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. *Bone Marrow Transplant* 1995; **16**: 393–399.
- 302 Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. *Chest* 1999; **115**: 901–905.
- 303 Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G *et al*. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. *MMWR Recomm Rep* 2007; **56** (RR-6): 1–54.
- 304 Centers for Disease Control and Prevention (CDC). Immunization of health care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee. *MMWR Morb Mortal Wkly Rep* 1997; **11**: 461–442.
- 305 Hayden FG. Prevention and treatment of influenza in immunocompromised patients. *Am J Med* 1997; **102**(3A): 55–60; discussion 75–76.
- 306 Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciú H *et al*. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. *Bone Marrow Transplant* 1993; **11**: 1–5.
- 307 Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G *et al*. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. *MMWR Recomm Rep* 2008; **57** (RR-7): 1–60.
- 308 American Academy of Pediatrics. Influenza. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 401–411.
- 309 Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. *Clin Infect Dis* 2004; **39**: 1300–1306.
- 310 Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ *et al*. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine (Baltimore)* 2006; **85**: 278–287.
- 311 Martin MA, Bock MJ, Pfaller MA, Wenzel RP. Respiratory syncytial virus infections in adult bone marrow transplant recipients. *Lancet* 1988; **1**: 1396–1397.
- 312 Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. *Medicine (Baltimore)* 1989; **68**: 269–281.
- 313 Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H *et al*. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. *Clin Infect Dis* 2007; **44**: 245–249.
- 314 Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D *et al*. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. *Clin Infect Dis* 2008; **46**: 402–412.
- 315 Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J, Ringden O, Winiarski J *et al*. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. *Bone Marrow Transplant* 1997; **19**: 905–908.
- 316 Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ *et al*. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* 2001; **28**: 479–484.
- 317 De Vincenzo JP, Leombruno D, Soiffer RJ, Siber GR. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. *Bone Marrow Transplant* 1996; **17**: 1051–1056.
- 318 de Fontbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C *et al*. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2007; **45**: 1019–1024.
- 319 American Academy of Pediatrics. Respiratory Syncytial Virus. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 560–566.
- 320 Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. *Am J Med* 1997; **102**(3A): 61–70; discussion 75–76.
- 321 Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA *et al*. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. *Ann Intern Med* 2006; **144**: 344–349.
- 322 Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin *in vitro*. *Antiviral Res* 2003; **60**: 51–59.
- 323 Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. *Antimicrob Agents Chemother* 2006; **50**: 774–777.
- 324 American Academy of Pediatrics. Parainfluenza Viral Infections. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on*

- Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 479–481.
- 325 American Academy of Pediatrics. Adenovirus Infections. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 202–204.
- 326 Horwitz MS. Adenoviruses. In: Knipe DM, Howley PM (eds). *Fields Virology*. Lippincott, Williams and Wilkins: Philadelphia, 2001, pp 2301–2326.
- 327 Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. *J Infect Dis* 1995; **171**: 1090–1096.
- 328 La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV *et al*. Adenovirus infections in adult recipients of blood and marrow transplants. *Clin Infect Dis* 2001; **32**: 871–876.
- 329 Howard DS, Phillips IG, Reece DE, Munn RK, Henslee-Downey J, Pittard M *et al*. Adenovirus infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 1999; **29**: 1494–1501.
- 330 Ison MG. Adenovirus infections in transplant recipients. *Clin Infect Dis* 2006; **43**: 331–339.
- 331 Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE *et al*. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. *Blood* 2002; **100**: 1619–1627.
- 332 Kampmann B, Cubitt D, Walls T, Naik P, Depala M, Samarasinghe S *et al*. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. *Br J Haematol* 2005; **130**: 595–603.
- 333 Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, Preuner S *et al*. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. *Blood* 2003; **102**: 1114–1120.
- 334 Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV *et al*. Increasing incidence of adenovirus disease in bone marrow transplant recipients. *J Infect Dis* 1994; **169**: 775–781.
- 335 Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. *N Engl J Med* 1985; **312**: 529–533.
- 336 Myers GD, Krance RA, Weiss H, Kuehnl I, Demmler G, Heslop HE *et al*. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). *Bone Marrow Transplant* 2005; **36**: 1001–1008.
- 337 Erard V, Huang ML, Ferrenberg J, Nguy L, Stevens-Ayers TL, Hackman RC *et al*. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. *Clin Infect Dis* 2007; **45**: 958–965.
- 338 Feuchtinger T, Lucke J, Hamprecht K, Richard C, Handgretinger R, Schumm M *et al*. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. *Br J Haematol* 2005; **128**: 503–509.
- 339 Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE *et al*. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007; **39**: 677–686.
- 340 van Tol MJ, Kroes AC, Schinkel J, Dinkelaar W, Claas EC, Jol-van der Zijde CM *et al*. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. *Bone Marrow Transplant* 2005; **36**: 39–50.
- 341 Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H *et al*. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. *Biol Blood Marrow Transplant* 2004; **10**: 186–194.
- 342 Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A *et al*. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. *Biol Blood Marrow Transplant* 2007; **13**: 74–81.
- 343 Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P *et al*. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. *Transplantation* 2006; **81**: 1398–1404.
- 344 Symeonidis N, Jakubowski A, Pierre-Louis S, Jaffe D, Pamer E, Sepkowitz K *et al*. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. *Transpl Infect Dis* 2007; **9**: 108–113.
- 345 Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P *et al*. *In vitro* susceptibility of adenovirus to antiviral drugs is species-dependent. *Antivir Ther* 2005; **10**: 225–229.
- 346 Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K *et al*. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. *Br J Haematol* 2006; **134**: 64–76.
- 347 Hirsch HH, Steiger J. Polyomavirus BK. *Lancet Infect Dis* 2003; **3**: 611–623.
- 348 Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). *Adv Exp Med Biol* 2006; **577**: 19–45.
- 349 Egli A, Infanti L, Stebler C, Bodaghi S, Gosert R, Hirsch HH. Polyomavirus BK (BKV) and JC (JCV) replication in plasma and urine in healthy blood donors (abstract no. 1058). *Am J Transplant* 2008; **8**(S2): 460.
- 350 Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. *J Virol* 2001; **75**: 10290–10299.
- 351 Knowles WA, Pillay D, Johnson MA, Hand JF, Brown DW. Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. *J Med Virol* 1999; **59**: 474–479.
- 352 Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of BK viraemia with hemorrhagic cystitis in recipients of bone marrow transplants. *N Engl J Med* 1986; **315**: 230–234.
- 353 Arthur RR, Shah KV, Charache P, Saral R. BK and JC virus infections in recipients of bone marrow transplants. *J Infect Dis* 1988; **158**: 563–569.
- 354 Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P *et al*. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. *J Clin Oncol* 1995; **13**: 1103–1109.
- 355 Gorczynska E, Turkiewicz D, Rybka K, Toporski J, Kalwak K, Dyla A *et al*. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2005; **11**: 797–804.
- 356 Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ *et al*. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med* 2002; **347**: 488–496.
- 357 Stracke S, Helmchen U, von Muller L, Bunjes D, Keller F. Polyoma virus-associated interstitial nephritis in a patient with acute myeloid leukaemia and peripheral blood stem cell transplantation. *Nephrol Dial Transplant* 2003; **18**: 2431–2433.
- 358 Limaye AP, Smith KD, Cook L, Groom DA, Hunt NC, Jerome KR *et al*. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. *Am J Transplant* 2005; **5**: 614–620.
- 359 Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R *et al*. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. *Transplantation* 2007; **84**: 323–330.
- 360 Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. *Bone Marrow Transplant* 2007; **39**: 101–107.
- 361 Hix JK, Braun WE, Isada CM. Delirium in a renal transplant recipient associated with BK virus in the cerebrospinal fluid. *Transplantation* 2004; **78**: 1407–1408.
- 362 Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. *Expert Rev Anti Infect Ther* 2007; **5**: 105–115.
- 363 Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL *et al*. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2005; **40**: 528–537.
- 364 Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW *et al*. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. *Blood* 2005; **106**: 464–469.

- 365 Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. *Blood* 2002; **99**: 4245–4246.
- 366 Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L *et al*. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. *Virology* 1988; **167**: 630–633.
- 367 Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. *Proc Natl Acad Sci USA* 1986; **83**: 1627–1631.
- 368 Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K *et al*. Rituximab-related viral infections in lymphoma patients. *Leuk Lymphoma* 2007; **48**: 1307–1312.
- 369 Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A *et al*. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. *J Med Virol* 2006; **78**: 1560–1563.
- 370 Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S *et al*. Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. *J Clin Virol* 2005; **32**: 173–178.
- 371 Goyama S, Kanda Y, Nannya Y, Kawazu M, Takeshita M, Niino M *et al*. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. *Leuk Lymphoma* 2002; **43**: 2159–2163.
- 372 Lau GK, Lie A, Liang R. Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy. *Blood* 2002; **100**: 3054.
- 373 Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A *et al*. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. *Blood* 2002; **99**: 2324–2330.
- 374 Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK *et al*. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. *Hepatology* 2002; **36**: 702–709.
- 375 Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC *et al*. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant* 2006; **12**: 84–94.
- 376 Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. *Int J Hematol* 2005; **81**: 349–351.
- 377 Shuhart MC, Myerson D, Childs BH, Fingerroth JD, Perry JJ, Snyder DS *et al*. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. *Blood* 1994; **84**: 3229–3235.
- 378 Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG *et al*. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. *Hepatology* 1999; **29**: 1893–1899.
- 379 de Latour RP, Levy V, Asselah T, Marcellin P, Scieux C, Ades L *et al*. Long-term outcome of hepatitis C infection after bone marrow transplantation. *Blood* 2004; **103**: 1618–1624.
- 380 Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. *Leuk Lymphoma* 1995; **17**: 245–249.
- 381 Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingerroth J, Ritz J. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. *Transplantation* 1996; **62**: 1358–1360.
- 382 Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K. Suppressing anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. *Am J Gastroenterol* 2007; **102**: 449–451.
- 383 McDonald GB. Review article: management of hepatic disease following haematopoietic cell transplant. *Aliment Pharmacol Ther* 2006; **24**: 441–452.
- 384 Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG *et al*. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. *Blood* 2004; **103**: 78–84.
- 385 de Latour RP, Asselah T, Levy V, Scieux C, Devergie A, Ribaud P *et al*. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. *Bone Marrow Transplant* 2005; **36**: 709–713.
- 386 Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y *et al*. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. *Lancet* 1988; **1**: 1065–1067.
- 387 Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. *Clin Infect Dis* 2005; **40**: 932–940.
- 388 Zerr DM, Meier AS, Selke SS, Frenkel LM, Huang ML, Wald A *et al*. A population-based study of primary human herpesvirus 6 infection. *N Engl J Med* 2005; **352**: 768–776.
- 389 Cone RW, Huang ML, Ashley R, Corey L. Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals. *J Clin Microbiol* 1993; **31**: 1262–1267.
- 390 Yoshikawa T, Asano Y, Kobayashi I, Nakashima T, Yazaki T, Suga S *et al*. Seroepidemiology of human herpesvirus 7 in healthy children and adults in Japan. *J Med Virol* 1993; **41**: 319–323.
- 391 Imbert-Marcille BM, Tang XW, Lepelletier D, Besse B, Moreau P, Billaudel S *et al*. Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. *Clin Infect Dis* 2000; **31**: 881–886.
- 392 Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohno K *et al*. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. *J Infect Dis* 2006; **193**: 68–79.
- 393 Sashihara J, Tanaka-Taya K, Tanaka S, Amo K, Miyagawa H, Hosoi G *et al*. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. *Blood* 2002; **100**: 2005–2011.
- 394 Wang LR, Dong LJ, Lu DP. Surveillance of active human herpesvirus 6 infection in chinese patients after hematopoietic stem cell transplantation with 3 different methods. *Int J Hematol* 2006; **84**: 262–267.
- 395 Ward KN, Leong HN, Nacheva EP, Howard J, Atkinson CE, Davies NW *et al*. Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. *J Clin Microbiol* 2006; **44**: 1571–1574.
- 396 Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH *et al*. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. *Neurology* 2007; **69**: 156–165.
- 397 Gorniak RJ, Young GS, Wiese DE, Marty FM, Schwartz RB. MR imaging of human herpesvirus-6-associated encephalitis in 4 patients with anterograde amnesia after allogeneic hematopoietic stem-cell transplantation. *AJNR* 2006; **27**: 887–891.
- 398 Glosston NL, Hudson AW. Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. *Virology* 2007; **365**: 125–135.
- 399 Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2002; **34**: 309–317.
- 400 De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. *Clin Microbiol Rev* 2005; **18**: 217–245.
- 401 de Medeiros BC, Rezuke WN, Ricci Jr A, Tsongalis G, Shen PU, Bona RD *et al*. Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. *Acta Haematologica* 2000; **104**: 115–118.
- 402 Bruno B, Sorasio R, Barozzi P, Vieira J, Omede P, Giaretta F *et al*. Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. *Eur J Haematol* 2006; **76**: 342–347.
- 403 Gentile G, Capobianchi A, Volpi A, Palu G, Pica F, Calistri A *et al*. Human herpesvirus 8 DNA in serum during seroconversion in allogeneic bone marrow transplant recipients. *J Natl Cancer Inst* 2005; **97**: 1008–1011.
- 404 Cuzzola M, Irrera G, Iacopino O, Cuzzocrea A, Messina G, Console G *et al*. Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation. *Clin Infect Dis* 2003; **37**: e102–e106.
- 405 Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S *et al*. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Cancer* 2004; **101**: 317–324.
- 406 Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ *et al*. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-asso-

References

- ciated lymphoma: AIDS Malignancy Consortium study 020. *Biol Blood Marrow Transplant* 2008; **14**: 59–66.
- 407 Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. *Lancet* 2000; **355**: 1071–1072.
- 408 Molina A, Krishnan AY, Nademane A, Zabner R, Sniecinski I, Zaia J *et al*. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. *Cancer* 2000; **89**: 680–689.
- 409 Krishnan A, Molina A, Zaia J, Nademane A, Kogut N, Rosenthal J *et al*. Autologous stem cell transplantation for HIV-associated lymphoma. *Blood* 2001; **98**: 3857–3859.
- 410 Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M *et al*. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2003; **21**: 4423–4427.
- 411 Gupta V, Tomblyn M, Pederson T, Thompson J, Gress R, Storek J *et al*. Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research (CIBMTR). *Biol Blood Marrow Transplant* 2009; **15**: 864–871.
- 412 American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. *J Clin Oncol* 1994; **12**: 2471–2508.
- 413 Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone marrow transplant recipients: worthwhile or wasteful? *Bone Marrow Transplant* 1995; **15**: 469–473.
- 414 Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. *NCI Monogr* 1990; **9**: 43–45.
- 415 Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A *et al*. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone Marrow Transplant* 2007; **40**: 451–456.
- 416 Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. *Br J Haematol* 2007; **139**: 519–531.
- 417 Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? *Clin Infect Dis* 2001; **33**: 1959–1967.
- 418 Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H *et al*. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. *N Engl J Med* 1992; **326**: 845–851.
- 419 Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR *et al*. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. *J Infect Dis* 1995; **171**: 1545–1552.
- 420 Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME *et al*. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. *Blood* 2000; **96**: 2055–2061.
- 421 Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM *et al*. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997–2005: an 8.5-year analysis of susceptibilities of *Candida* species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. *J Clin Microbiol* 2007; **45**: 1735–1745.
- 422 Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. *J Infect Dis* 2000; **181**: 309–316.
- 423 Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of *Candida glabrata* to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. *J Clin Microbiol* 2004; **42**: 3142–3146.
- 424 Tsai HF, Bard M, Izumikawa K, Krol AA, Sturm AM, Culbertson NT *et al*. *Candida glabrata* *erg1* mutant with increased sensitivity to azoles and to low oxygen tension. *Antimicrob Agents Chemother* 2004; **48**: 2483–2489.
- 425 van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH *et al*. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. *Clin Infect Dis* 2004; **39**: 1407–1416.
- 426 Perlin DS. Resistance to echinocandin-class antifungal drugs. *Drug Resist Updat* 2007; **10**: 121–130.
- 427 Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL *et al*. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. *Ann Intern Med* 2003; **138**: 705–713.
- 428 Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L *et al*. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* 2006; **38**: 127–134.
- 429 Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR *et al*. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007; **356**: 335–347.
- 430 Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID *et al*. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. *Blood* 2007; **110**: 55a.
- 431 Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis—a contraindication to marrow transplantation? *Blood* 1994; **84**: 2811–2814.
- 432 Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A *et al*. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2007; **13**: 760–764.
- 433 Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA *et al*. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. *Blood* 2004; **103**: 1527–1533.
- 434 Denning DW. Invasive aspergillosis. *Clin Infect Dis* 1998; **26**: 781–803; quiz 804–805.
- 435 Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Muller FM *et al*. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. *Clin Infect Dis* 2001; **33**: 1871–1878.
- 436 Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Mahfouz TH, Rex JH *et al*. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized *Aspergillus* species and other opportunistic molds. *Clin Infect Dis* 2002; **35**: E86–E88.
- 437 Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH *et al*. Pathogenic molds (including *Aspergillus* species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. *Blood* 2003; **101**: 2542–2546.
- 438 Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP *et al*. Pathogenic *Aspergillus* species recovered from a hospital water system: a 3-year prospective study. *Clin Infect Dis* 2002; **34**: 780–789.
- 439 Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. *Clin Infect Dis* 2001; **32**: 1319–1324.
- 440 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2002; **34**: 909–917.
- 441 Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S *et al*. Fusarium infection in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2004; **38**: 1237–1242.
- 442 Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP *et al*. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. *Int J Antimicrob Agents* 2007; **30**: 551–554.
- 443 Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. *Clin Infect Dis* 2008; **46**: 120–128.
- 444 Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduyn JK, Hop WC *et al*. Aerosolized liposomal amphotericin B for the prevention of

- invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. *Clin Infect Dis* 2008; **46**: 1401–1408.
- 445 Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S *et al.* Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. *Bone Marrow Transplant* 2004; **33**: 943–948.
- 446 Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B *et al.* Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. *J Clin Oncol* 2003; **21**: 4615–4626.
- 447 Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. *Pharmacotherapy* 2007; **27**: 1627–1636.
- 448 Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin Infect Dis* 2008; **46**: 201–211.
- 449 Cirino CM, Leitman SF, Williams E, Fedorko D, Palmore TN, Klion A *et al.* Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. *Ann Intern Med* 2008; **148**: 794–795.
- 450 Budak-Alpdogan T, Tangun Y, Kalayoglu-Besik S, Ratip S, Akan H, Baslar Z *et al.* The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. *Biol Blood Marrow Transplant* 2000; **6**: 370–374.
- 451 Ip MS, Yuen KY, Woo PC, Luk WK, Tsang KW, Lam WK *et al.* Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. *Am J Respir Crit Care Med* 1998; **158**: 1173–1177.
- 452 Erdstein AA, Daas P, Bradstock KF, Robinson T, Hertzberg MS. Tuberculosis in allogeneic stem cell transplant recipients: still a problem in the 21st century. *Transpl Infect Dis* 2004; **6**: 142–146.
- 453 Garces Ambrossi G, Jakubowski A, Feinstein MB, Weinstock DM. Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. *Bone Marrow Transplant* 2005; **36**: 741–743.
- 454 de la Camara R, Martino R, Granados E, Rodriguez-Salvanes FJ, Rovira M, Cabrera R *et al.* Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. *Bone Marrow Transplant* 2000; **26**: 291–298.
- 455 Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. *J Hosp Infect* 2006; **62**: 421–426.
- 456 Yuen KY, Woo PC. Tuberculosis in blood and marrow transplant recipients. *Hematol Oncol* 2002; **20**: 51–62.
- 457 Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, Ward MS *et al.* Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. *Clin Infect Dis* 2004; **38**: 1229–1236.
- 458 Saadeh CE, Srkalovic G. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia. *Pharmacotherapy* 2008; **28**: 281–284.
- 459 Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. *MMWR Recomm Rep* 2002; **51**(RR-8): 1–52.
- 460 Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. *MMWR Recomm Rep* 2005; **54**(RR-15): 1–47.
- 461 Centers for Disease Control and Prevention (CDC). The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. *MMWR Recomm Rep* 1996; **45**(RR-4): 1–18.
- 462 American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR Recomm Rep* 2000; **49**(RR-6): 1–51.
- 463 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med* 2007; **146**: 340–354.
- 464 Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a *Mycobacterium tuberculosis* antigen-specific interferon gamma assay. *Ann Rheum Dis* 2008; **67**: 84–90.
- 465 An Advisory Committee Statement (ACS). Interferon gamma release assays for latent tuberculosis infection. *Can Commun Dis Rep* 2007; **33**(ACS-10): 1–18.
- 466 Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. *Eur Respir J* 2007; **30**: 945–950.
- 467 Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH *et al.* Tuberculosis in hematopoietic stem cell transplant recipients in Korea. *Int J Hematol* 2004; **79**: 185–188.
- 468 Ahmed P, Anwar M, Khan B, Altaf C, Ullah K, Raza S *et al.* Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients. *J Pak Med Assoc* 2005; **55**: 378–381.
- 469 Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 735–739.
- 470 Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2006; **55**(RR-15): 1–48.
- 471 Brazinsky JH, Phillips JE. Pneumocystis pneumonia transmission between patients with lymphoma. *JAMA* 1969; **209**: 1527.
- 472 Chave JP, David S, Wauters JP, Van Melle G, Francioli P. Transmission of *Pneumocystis carinii* from AIDS patients to other immunosuppressed patients: a cluster of *Pneumocystis carinii* pneumonia in renal transplant recipients. *AIDS* 1991; **5**: 927–932.
- 473 Goesch TR, Gotz G, Stellbrinck KH, Albrecht H, Weh HJ, Hossfeld DK. Possible transfer of *Pneumocystis carinii* between immunodeficient patients. *Lancet* 1990; **336**: 627.
- 474 Bensousan T, Garo B, Islam S, Bourbigot B, Cledes J, Garre M. Possible transfer of *Pneumocystis carinii* between kidney transplant recipients. *Lancet* 1990; **336**: 1066–1067.
- 475 Ruskin J, Remington JS. The compromised host and infection. I. *Pneumocystis carinii* pneumonia. *JAMA* 1967; **202**: 1070–1074.
- 476 Watanabe JM, Chinchinian H, Weitz C, McIvanie SK. *Pneumocystis carinii* Pneumonia in a Family. *JAMA* 1965; **193**: 685–686.
- 477 Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto S, Munoz MP *et al.* Transmission of *Pneumocystis carinii* DNA from a patient with *P. carinii* pneumonia to immunocompetent contact health care workers. *J Clin Microbiol* 2000; **38**: 1536–1538.
- 478 Wohl AR, Simon P, Hu YW, Duchin JS. The role of person-to-person transmission in an epidemiologic study of *Pneumocystis carinii* pneumonia. *AIDS* 2002; **16**: 1821–1825.
- 479 Miller RF, Ambrose HE, Novelli V, Wakefield AE. Probable mother-to-infant transmission of *Pneumocystis carinii* f. sp. hominis infection. *J Clin Microbiol* 2002; **40**: 1555–1557.
- 480 Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Risk for *Pneumocystis carinii* transmission among patients with pneumonia: a molecular epidemiology study. *Emerg Infect Dis* 2003; **9**: 132–134.
- 481 Tuan IZ, Dennison D, Weisdorf DJ. *Pneumocystis carinii* pneumonitis following bone marrow transplantation. *Bone Marrow Transplant* 1992; **10**: 267–272.
- 482 De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E *et al.* Occurrence of *Pneumocystis jiroveci* pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. *Bone Marrow Transplant* 2005; **36**: 879–883.
- 483 Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK *et al.* Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003; **32**: 515–522.
- 484 Lyytikäinen O, Ruutu T, Volin L, Lautenschlager I, Jokipii L, Tiittanen L *et al.* Late onset *Pneumocystis carinii* pneumonia following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1996; **17**: 1057–1059.
- 485 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for *Pneumocystis pneumonia* (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst Rev* 2007, CD005590.
- 486 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of *Pneumocystis pneumonia* in immunocompromised non-HIV-infected patients:

- systematic review and meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2007; **82**: 1052–1059.
- 487 Maltzou HC, Petropoulos D, Choroszy M, Gardner M, Mantzouranis EC, Rolston KV *et al*. Dapsone for *Pneumocystis carinii* prophylaxis in children undergoing bone marrow transplantation. *Bone Marrow Transplant* 1997; **20**: 879–881.
- 488 Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M *et al*. Toxicity and efficacy of daily dapsone as *Pneumocystis jirovecii* prophylaxis after hematopoietic stem cell transplantation: a case-control study. *Biol Blood Marrow Transplant* 2005; **11**: 521–529.
- 489 Link H, Vohringer HF, Wingen F, Bragas B, Schwardt A, Ehninger G. Pentamidine aerosol for prophylaxis of *Pneumocystis carinii* pneumonia after BMT. *Bone Marrow Transplant* 1993; **11**: 403–406.
- 490 Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA *et al*. Atovaquone suspension compared with aerosolized pentamidine for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. *J Infect Dis* 1999; **180**: 369–376.
- 491 Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of *Pneumocystis carinii* pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. *Clin Infect Dis* 1999; **29**: 1467–1471.
- 492 Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. *Ann Intern Med* 1984; **100**: 512–514.
- 493 Walter E, Chauncey T, Boeckh M, Hackman B, Kennedy M, Bowden R. PCP prophylaxis after marrow transplantation: efficacy of trimethoprim-sulfamethoxazole (trim-sulfa), role of trim-sulfa desensitization and iv pentamidine. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993, p 125.
- 494 Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. *Biol Blood Marrow Transplant* 2000; **6**: 35–43.
- 495 Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJ *et al*. Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. *Clin Infect Dis* 1992; **15**: 267–270.
- 496 Siegel SE, Lunde MN, Gelderman AH, Halterman RH, Brown JA, Levine AS *et al*. Transmission of toxoplasmosis by leukocyte transfusion. *Blood* 1971; **37**: 388–394.
- 497 Jurges E, Young Y, Eltumi M, Holliman RE, Vellodi A, Rogers TR *et al*. Transmission of toxoplasmosis by bone marrow transplant associated with Campath-1G. *Bone Marrow Transplant* 1992; **9**: 65–66.
- 498 Chandrasekar PH, Momin F. Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team. *Bone Marrow Transplant* 1997; **19**: 685–689.
- 499 Bretagne S, Costa JM, Foulet F, Jabot-Lestang L, Baud-Camus F, Cordonnier C. Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem cell transplant recipients. *Transpl Infect Dis* 2000; **2**: 127–132.
- 500 Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R *et al*. Early detection of *Toxoplasma gondii* in peripheral blood samples after allogeneic stem cell transplantation. *Clin Infect Dis* 2005; **40**: 67–78.
- 501 Lim Z, Baker B, Zuckerman M, Wade JJ, Ceasay M, Ho AY *et al*. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. *J Infect* 2007; **54**: e83–e86.
- 502 Small TN, Leung L, Stiles J, Kiehn TE, Malak SA, O'Reilly RJ *et al*. Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation. *Bone Marrow Transplant* 2000; **25**: 969–973.
- 503 Costa JM, Munoz C, Kruger D, Martino R, Held TK, Darde ML *et al*. Quality control for the diagnosis of *Toxoplasma gondii* reactivation in SCT patients using PCR assays. *Bone Marrow Transplant* 2001; **28**: 527–528.
- 504 Ionita C, Wasay M, Balos L, Bakshi R. MR imaging in toxoplasmosis encephalitis after bone marrow transplantation: paucity of enhancement despite fulminant disease. *AJNR Am J Neuroradiol* 2004; **25**: 270–273.
- 505 Roemer E, Blau IW, Basara N, Kiehl NG, Bischoff M, Gunzelmann S *et al*. Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-center experience. *Clin Infect Dis* 2001; **32**: E1–E8.
- 506 Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. *Bone Marrow Transplant* 1994; **14**: 241–245.
- 507 Peacock JJE, Greven CM, Cruz JM, Hurd DD. Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? *Bone Marrow Transplant* 1995; **15**: 983–987.
- 508 Daly AS, McGeer A, Lipton JH. Systemic nocardiosis following allogeneic bone marrow transplantation. *Transpl Infect Dis* 2003; **5**: 16–20.
- 509 Filice GA. Nocardiosis in persons with human immunodeficiency virus infection, transplant recipients, and large, geographically defined populations. *J Lab Clin Med* 2005; **145**: 156–162.
- 510 van Burik J, Hackman RC, Nadeem SQ, Hiemenz JW, White MH, Flowers MED *et al*. Nocardiosis after bone marrow transplantation: a Retrospective Study. *Clin Infect Dis* 1997; **24**: 1154–1160.
- 511 Martinez Tomas R, Menendez Villanueva R, Reyes Calzada S, Santos Durantez M, Valles Tarazona JM, Modesto Alapont M *et al*. Pulmonary nocardiosis: risk factors and outcomes. *Respirology* 2007; **12**: 394–400.
- 512 Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA *et al*. Risk factors, clinical characteristics, and outcome of nocardia infection in organ transplant recipients: a matched case-control study. *Clin Infect Dis* 2007; **44**: 1307–1314.
- 513 Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections. *Infect Dis Clin North Am* 1993; **7**: 655–682.
- 514 Conway DJ, Atkins NS, Lillywhite JE, Bailey JW, Robinson RD, Lindo JF *et al*. Immunodiagnosis of *Strongyloides stercoralis* infection: a method for increasing the specificity of the indirect ELISA. *Trans R Soc Trop Med Hyg* 1993; **87**: 173–176.
- 515 Boscolo M, Gobbo M, Mantovani W, Degani M, Anselmi M, Monteiro GB *et al*. Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. *Clin Vaccine Immunol* 2007; **14**: 129–133.
- 516 Schaffel R, Nucci M, Carvalho E, Braga M, Almeida L, Portugal R *et al*. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. *Am J Trop Med Hyg* 2001; **65**: 346–350.
- 517 Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. *Clin Microbiol Rev* 2004; **17**: 208–217.
- 518 Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. *Transfusion* 1999; **39**: 310–315.
- 519 Sirvent-von Buelzingsloewen A, Marty P, Rosenthal E, Delaunay P, Allieri-Rosenthal A, Gratecos N *et al*. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. *Bone Marrow Transplant* 2004; **33**: 667–668.
- 520 Agteresch HJ, van 't Veer MB, Cornelissen JJ, Sluifers JF. Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007; **40**: 391–393.
- 521 Rodriguez-Wilhelmi P, Panizo C, Ruza E, Rocha E. Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients. *Med Clin (Barc)* 2001; **116**: 37–38.
- 522 Dictar M, Sinagra A, Veron MT, Luna C, Dengra C, De Rissio A *et al*. Recipients and donors of bone marrow transplants suffering from Chagas' disease: management and preemptive therapy of parasitemia. *Bone Marrow Transplant* 1998; **21**: 391–393.
- 523 Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. *Rev Soc Bras Med Trop* 2003; **36**: 767–771.
- 524 Moraes-Souza H, Bordin JO. Strategies for prevention of transfusion-associated Chagas' disease. *Transfus Med Rev* 1996; **10**: 161–170.
- 525 Altclas J, Sinagra A, Jaimovich G, Salgueira C, Luna C, Requejo A *et al*. Reactivation of chronic Chagas' disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole. *Transpl Infect Dis* 1999; **1**: 135–137.
- 526 Altclas J, Sinagra A, Dictar M, Luna C, Veron MT, De Rissio AM *et al*. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. *Bone Marrow Transplant* 2005; **36**: 123–129.
- 527 World Health Organization. *World Malaria Report 2008*. World Health Organization: Geneva, Switzerland, 2008.

- 528 Shamsi T, Hashmi K, Adil S, Ahmad P, Irfan M, Raza S *et al.* The stem cell transplant program in Pakistan—the first decade. *Bone Marrow Transplant* 2008; **42**(Suppl 1): S114–S117.
- 529 D'Alessandro U, Olaleye BO, McGuire W, Thomson MC, Langerock P, Bennett S *et al.* A comparison of the efficacy of insecticide-treated and untreated bed nets in preventing malaria in Gambian children. *Trans R Soc Trop Med Hyg* 1995; **89**: 596–598.
- 530 Hill N, Lenglet A, Arnez AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. *BMJ* 2007; **335**: 1023.
- 531 Schulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep* 2003; **52**(RR-10): 1–42.
- 532 American Institute of Architects Facility Guidelines Institute, AIA Academy of Architecture for Health, US Department of Health & Human Services. *Guidelines for Design and Construction of Health Care Facilities*. American Institute of Architects Press: Washington DC, 2006, p 352.
- 533 Rhame FS, Streifel AJ, Kersey Jr JH, McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection. *Am J Med* 1984; **76**(5A): 42–52.
- 534 Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. *MMWR Recomm Rep* 2004; **53**(RR-3): 1–36.
- 535 Benet T, Nicolle MC, Thiebaut A, Piens MA, Nicolini FE, Thomas X *et al.* Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. *Clin Infect Dis* 2007; **45**: 682–686.
- 536 Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy Jr PL. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. *Infect Control Hosp Epidemiol* 2002; **23**: 525–531.
- 537 Rice N, Streifel A, Vesley D. An evaluation of hospital special-ventilation-room pressures. *Infect Control Hosp Epidemiol* 2001; **22**: 19–23.
- 538 Engelhart S, Hanfland J, Glasmacher A, Krizek L, Schmidt-Wolf IG, Exner M. Impact of portable air filtration units on exposure of haematology-oncology patients to airborne *Aspergillus fumigatus* spores under field conditions. *J Hosp Infect* 2003; **54**: 300–304.
- 539 Rutala WA. APIC guideline for selection and use of disinfectants. 1994, 1995, and 1996 APIC Guidelines Committee. Association for Professionals in Infection Control and Epidemiology, Inc. *Am J Infect Control* 1996; **24**: 313–342.
- 540 Loo VG, Bertrand C, Dixon C, Vitte D, DeSalis B, McLean AP *et al.* Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. *Infect Control Hosp Epidemiol* 1996; **17**: 360–364.
- 541 Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. *J Hosp Infect* 1989; **14**: 89–94.
- 542 Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, Coureul MH *et al.* Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against *Aspergillus* airborne contamination during hospital renovation. *Infect Control Hosp Epidemiol* 1999; **20**: 508–513.
- 543 Thio CL, Smith D, Merz WG, Streifel AJ, Bova G, Gay L *et al.* Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. *Infect Control Hosp Epidemiol* 2000; **21**: 18–23.
- 544 Kistemann T, Huneburg H, Exner M, Vacata V, Engelhart S. Role of increased environmental *Aspergillus* exposure for patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids in an intensive care unit. *Int J Hyg Environ Health* 2002; **204**: 347–351.
- 545 Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. *Am J Transplant* 2002; **2**: 575–580.
- 546 Streifel AJ. Design and maintenance of hospital ventilation systems and the prevention of airborne infections. In: Mayhall C (ed). *Hospital Epidemiology and Infection Control*, 3rd edn. Lippincott, Williams & Wilkins: Philadelphia, 2004.
- 547 Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. *Eur J Epidemiol* 1989; **5**: 131–142.
- 548 Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. *J Hosp Infect* 2006; **63**: 246–254.
- 549 Bartley J. Prevention of infections related to construction, renovation, and demolition systems. In: Mayhall C (ed). *Hospital Epidemiology and Infection Control*, 3rd edn. Lippincott, Williams & Wilkins: Philadelphia, 2004.
- 550 Kidd F, Buttner C, Kressel AB. Construction: a model program for infection control compliance. *Am J Infect Control* 2007; **35**: 347–350.
- 551 Srinivasan A, Beck C, Buckley T, Geyh A, Bova G, Merz W *et al.* The ability of hospital ventilation systems to filter *Aspergillus* and other fungi following a building implosion. *Infect Control Hosp Epidemiol* 2002; **23**: 520–524.
- 552 Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R *et al.* Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. *Clin Microbiol Infect* 2006; **12**: 738–744.
- 553 Raad I, Hanna H, Osting C, Hachem R, Umphrey J, Tarrand J *et al.* Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. *Infect Control Hosp Epidemiol* 2002; **23**: 41–43.
- 554 Cooper EE, O'Reilly MA, Guest DI, Dharmage SC. Influence of building construction work on *Aspergillus* infection in a hospital setting. *Infect Control Hosp Epidemiol* 2003; **24**: 472–476.
- 555 Mahieu LM, De Dooy JJ, Van Laer FA, Jansens H, Ieven MM. A prospective study on factors influencing aspergillus spore load in the air during renovation works in a neonatal intensive care unit. *J Hosp Infect* 2000; **45**: 191–197.
- 556 Weems Jr JJ, Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. *Infect Control* 1987; **8**: 71–75.
- 557 Nihtinen A, Anttila VJ, Richardson M, Meri T, Volin L, Ruutu T. The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. *Bone Marrow Transplant* 2007; **40**: 457–460.
- 558 Falvey DG, Streifel AJ. Ten-year air sample analysis of *Aspergillus* prevalence in a university hospital. *J Hosp Infect* 2007; **67**: 35–41.
- 559 Lai KK. A cluster of invasive aspergillosis in a bone marrow transplant unit related to construction and the utility of air sampling. *Am J Infect Control* 2001; **29**: 333–337.
- 560 Morris G, Kokki MH, Anderson K, Richardson MD. Sampling of *Aspergillus* spores in air. *J Hosp Infect* 2000; **44**: 81–92.
- 561 Streifel AJ. *Aspergillus* and construction. In: Kundsinn RB (ed). *Architectural Design and Indoor Microbial Pollution*. Oxford University Press: New York, NY, 1988, pp 198–216.
- 562 Opal SM, Asp AA, Cannady Jr PB, Morse PL, Burton LJ, Hammer PG. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. *J Infect Dis* 1986; **153**: 634–637.
- 563 Lee I, Barton TD. Viral respiratory tract infections in transplant patients: epidemiology, recognition and management. *Drugs* 2007; **67**: 1411–1427.
- 564 Curtis L, Cali S, Conroy L. *Aspergillus* surveillance project at a large tertiary-care hospital. *J Hosp Infect* 2005; **59**: 188–196.
- 565 Dettenkofer M, Wenzler S, Amthor S, Antes G, Motschall E, Daschner FD. Does disinfection of environmental surfaces influence nosocomial infection rates? A systematic review. *Am J Infect Control* 2004; **32**: 84–89.
- 566 Rutala WA, Weber DJ. The benefits of surface disinfection. *Am J Infect Control* 2004; **32**: 226–231.
- 567 Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet contamination. *Infect Control Hosp Epidemiol* 1994; **15**(Part 1): 221–223.
- 568 Richet HM, McNeil MM, Davis BJ, Duncan E, Strickler J, Nunley D *et al.* *Aspergillus fumigatus* sternal wound infections in patients undergoing open heart surgery. *Am J Epidemiol* 1992; **135**: 48–58.
- 569 Pegues CF, Daar ES, Murthy AR. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital. *Infect Control Hosp Epidemiol* 2001; **22**: 370–374.
- 570 Noskin GA, Bednarz P, Suriano T, Reiner S, Peterson LR. Persistent contamination of fabric-covered furniture by vancomycin-resistant enterococci: Implications for upholstery selection in hospitals. *Am J Infect Control* 2000; **28**: 311–313.

References

- 571 Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999; **20**: 250–278; quiz 279–280.
- 572 Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A *et al*. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. *Bone Marrow Transplant* 1998; **21**: 1231–1238.
- 573 Dadd G, McMinn P, Monterosso L. Protective isolation in hemopoietic stem cell transplants: a review of the literature and single institution experience. *J Pediatr Oncol Nurs* 2003; **20**: 293–300.
- 574 Gupta A, Della-Latta P, Todd B, San Gabriel P, Haas J, Wu F *et al*. Outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit linked to artificial nails. *Infect Control Hosp Epidemiol* 2004; **25**: 210–215.
- 575 Moolenaar RL, Crutcher JM, San Joaquin VH, Sewell LV, Hutwagner LC, Carson LA *et al*. A prolonged outbreak of *Pseudomonas aeruginosa* in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? *Infect Control Hosp Epidemiol* 2000; **21**: 80–85.
- 576 Boszczowski I, Nicoletti C, Puccini DM, Pinheiro M, Soares RE, Van der Heijden IM *et al*. Outbreak of extended spectrum beta-lactamase-producing *Klebsiella pneumoniae* infection in a neonatal intensive care unit related to onychomycosis in a health care worker. *Pediatr Infect Dis J* 2005; **24**: 648–650.
- 577 Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S *et al*. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. *Lancet* 2000; **356**: 1307–1312.
- 578 Widmer AF. Replace hand washing with use of a waterless alcohol hand rub? *Clin Infect Dis* 2000; **31**: 136–143.
- 579 Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. *MMWR Recomm Rep* 2002; **51**(RR-16): 1–45, quiz CE1–4.
- 580 Bischoff WE, Reynolds TM, Sessler CN, Edmond MB, Wenzel RP. Handwashing compliance by health care workers: the impact of introducing an accessible, alcohol-based hand antiseptic. *Arch Intern Med* 2000; **160**: 1017–1021.
- 581 Hugonnet S, Perneger TV, Pittet D. Alcohol-based hand rub improves compliance with hand hygiene in intensive care units. *Arch Intern Med* 2002; **162**: 1037–1043.
- 582 National Antimicrobial Information Network List of EPA registered products.
- 583 CDC/National Center for Infectious Diseases/Hospital Infections Program. *Sterilization or Disinfection of Medical Devices: General Purposes*. US Department of Health and Human Services, CDC: Atlanta, GA, 2000.
- 584 Favero M, Bond W. Chapter 24: sterilization, disinfection, and antiseptics in the hospital. In: Hauser Jr WJ, Herrman JL, Isenberg HD, Shadomy HJ (eds). *Manual of Clinical Microbiology*. American Society for Microbiology: Washington DC, 1991 pp 183–200.
- 585 Johnson S, Gerding D. Chapter 29: *Clostridium difficile*. In: Mayhall CG (ed). *Hospital Epidemiology and Infection Control*. Lippincott Williams & Wilkins: Philadelphia, PA, 1999, pp 467–476.
- 586 Rutala WA, Weber DJ. Disinfection of endoscopes: review of new chemical sterilants used for high-level disinfection. *Infect Control Hosp Epidemiol* 1999; **20**: 69–76.
- 587 Centers for Disease Control and Prevention (CDC). Nosocomial outbreak of *Rhizopus* infections associated with Elastoplast wound dressings-Minnesota. *MMWR Morb Mortal Wkly Rep* 1978; **27**: 33–34.
- 588 Centers for Disease Control and Prevention (CDC). Follow-up on *Rhizopus* infections associated with Elastoplast bandages-United States. *MMWR Morb Mortal Wkly Rep* 1978; **27**: 243–244.
- 589 Bryce EA, Walker M, Scharf S, Lim AT, Walsh A, Sharp N *et al*. An outbreak of cutaneous aspergillosis in a tertiary-care hospital. *Infect Control Hosp Epidemiol* 1996; **17**: 170–172.
- 590 McCarty JM, Flam MS, Pullen G, Jones R, Kassel SH. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. *J Pediatr* 1986; **108**(Part 1): 721–724.
- 591 Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM. Nosocomial infection with *Rhizopus microsporus* in preterm infants: association with wooden tongue depressors. *Lancet* 1996; **348**: 441–443.
- 592 Staib F. Ecological and epidemiological aspects of aspergilli pathogenic for man and animal in Berlin (West). *Zentralbl Bakteriol Mikrobiol Hyg A* 1984; **257**: 240–245.
- 593 Hutto C, Little EA, Ricks R, Lee JD, Pass RF. Isolation of cytomegalovirus from toys and hands in a day care center. *J Infect Dis* 1986; **154**: 527–530.
- 594 Rogers M, Weinstock DM, Eagan J, Kiehn T, Armstrong D, Sepkowitz KA. Rotavirus outbreak on a pediatric oncology floor: possible association with toys. *Am J Infect Control* 2000; **28**: 378–380.
- 595 Fleming K, Randle J. Toys—friend or foe? A study of infection risk in a paediatric intensive care unit. *Paediatr Nurs* 2006; **18**: 14–18.
- 596 Davies MW, Mehr S, Garland ST, Morley CJ. Bacterial colonization of toys in neonatal intensive care cots. *Pediatrics* 2000; **106**: E18.
- 597 Buttery JP, Alabaster SJ, Heine RG, Scott SM, Crutchfield RA, Bigham A *et al*. Multiresistant *Pseudomonas aeruginosa* outbreak in a pediatric oncology ward related to bath toys. *Pediatr Infect Dis J* 1998; **17**: 509–513.
- 598 Centers for Disease Control and Prevention (CDC). *ABC's of Safe and Healthy Child Care: An On-Line Handbook for Child Care Providers*. US Department of Health and Human Services, CDC: Atlanta, GA, 2000.
- 599 Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchmann SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1998; **19**: 407–463.
- 600 Stover BH, Bratcher DF. Varicella-zoster virus: infection, control, and prevention. *Am J Infect Control* 1998; **26**: 369–381; quiz 382–384.
- 601 Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. *MMWR Recomm Rep* 1991; **40**(RR-8): 1–9.
- 602 AIDS/TB Committee of the Society for Healthcare Epidemiology of America. Management of healthcare workers infected with hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or other bloodborne pathogens. *Infect Control Hosp Epidemiol* 1997; **18**: 349–363.
- 603 Centers for Disease Control and Prevention (CDC). *Infection Control Guidance for the Prevention and Control of Influenza in Acute-Care Facilities*. Centers for Disease Control and Prevention: Atlanta, GA, 2007.
- 604 Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gour-Banacloche J *et al*. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. *Biol Blood Marrow Transplant* 2006; **12**: 375–396.
- 605 Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE *et al*. Updated clinical practice guidelines for the prevention and treatment of mucositis. *Cancer* 2007; **109**: 820–831.
- 606 Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. *Support Care Cancer* 1999; **7**: 17–20.
- 607 Schubert MM, Peterson DE, Lloid ME. Oral complications. In: Thomas ED, Blume KG, Forman SJ (eds). *Hematopoietic Cell Transplantation*, 2nd edn. Blackwell Science, Inc.: Oxford, UK, 1999, pp 751–763.
- 608 Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S *et al*. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. *J Clin Oncol* 2007; **25**: 2464–2472.
- 609 Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR *et al*. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clin Proc* 2006; **81**: 1047–1053.
- 610 Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. *Lancet Oncol* 2006; **7**: 508–514.
- 611 Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T *et al*. Palifermin for oral mucositis after intensive therapy for hematologic cancers. *N Engl J Med* 2004; **351**: 2590–2598.

- 612 Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J *et al.* Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. *Cancer* 2004; **100**(9 Suppl): 2026–2046.
- 613 Schubert MM, Correa ME. Oral graft-versus-host disease. *Dent Clin North Am* 2008; **52**: 79–109, viii–ix.
- 614 Do AN, Ray BJ, Banerjee SN, Illian AF, Barnett BJ, Pham MH *et al.* Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. *J Infect Dis* 1999; **179**: 442–448.
- 615 Kool JL, Fiore AE, Kioski CM, Brown EW, Benson RF, Pruckler JM *et al.* More than 10 years of unrecognized nosocomial transmission of Legionnaires' disease among transplant patients. *Infect Control Hosp Epidemiol* 1998; **19**: 898–904.
- 616 Oren I, Zuckerman T, Avivi I, Finkelstein R, Yigla M, Rowe JM. Nosocomial outbreak of Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control. *Bone Marrow Transplant* 2002; **30**: 175–179.
- 617 Knirsch CA, Jakob K, Schoonmaker D, Kiehlbauch JA, Wong SJ, Della-Latta P *et al.* An outbreak of Legionella micdadei pneumonia in transplant patients: evaluation, molecular epidemiology, and control. *Am J Med* 2000; **108**: 290–295.
- 618 Centers for Disease Control and Prevention (CDC). Sustained transmission of nosocomial Legionnaires disease—Arizona and Ohio. *MMWR Morb Mortal Wkly Rep* 1997; **46**: 416–421.
- 619 Palmore TN, Stock F, White M, Bordner M, Michelin A, Bennett JE *et al.* A cluster of cases of nosocomial legionnaires disease linked to contaminated hospital decorative water fountain. *Infect Control Hosp Epidemiol* 2009; **30**: 764–768.
- 620 Squier CL, Stout JE, Krsyotfiak S, McMahon J, Wagener MM, Dixon B *et al.* A proactive approach to prevention of health care-acquired Legionnaires' disease: the Allegheny County (Pittsburgh) experience. *Am J Infect Control* 2005; **33**: 360–367.
- 621 Stout JE, Muder RR, Mietzner S, Wagener MM, Perri MB, DeRoos K *et al.* Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations. *Infect Control Hosp Epidemiol* 2007; **28**: 818–824.
- 622 Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM *et al.* SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. *Infect Control Hosp Epidemiol* 2003; **24**: 362–386.
- 623 Dutch Workingparty Infection Prevention. Policy for Methicillin-resistant Staphylococcus aureus. *The Lancet Infectious Diseases* 2005; **5**: 653–663.
- 624 Siegel JD, Rhinehart E, Jackson M, Chiarello L. *Management of Multidrug-Resistant Organisms in Healthcare Settings*, 2006. CDC: Atlanta, Georgia, 2006.
- 625 Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H *et al.* Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. *J Hosp Infect* 2006; **63**(Suppl 1): S1–S44.
- 626 Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C *et al.* Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. *JAMA* 2008; **299**: 1149–1157.
- 627 Robicsek A, Beaumont JL, Paule SM, Hacek DM, Thomson Jr RB, Kaul KL *et al.* Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. *Ann Intern Med* 2008; **148**: 409–418.
- 628 Huang SS, Yokoe DS, Hinrichsen VL, Spurchise LS, Datta R, Miroshnik I *et al.* Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. *Clin Infect Dis* 2006; **43**: 971–978.
- 629 Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. *Infect Control Hosp Epidemiol* 2007; **28**: 1155–1161.
- 630 Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. *Antimicrob Agents Chemother* 1999; **43**: 1412–1416.
- 631 Simor AE, Loeb M. The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper. *Can J Infect Dis* 2004; **15**: 39–48.
- 632 Leski TA, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski K, Hryniewicz W. Outbreak of mupirocin-resistant Staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. *J Clin Microbiol* 1999; **37**: 2781–2788.
- 633 Schmitz F, Lindenlauf E, Hofmann B, Fluit A, Verhoef J, Heinz H *et al.* The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. *J Antimicrob Chemother* 1998; **42**: 489–495.
- 634 Irish D, Eltringham I, Teall A, Pickett H, Farelly H, Reith S *et al.* Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. *J Hosp Infect* 1998; **39**: 19–26.
- 635 Udo EE, Jacob LE, Mathew B. The spread of a mupirocin-resistant/methicillin-resistant Staphylococcus aureus clone in Kuwait hospitals. *Acta Tropica* 2001; **80**: 155–161.
- 636 Bastos MD, Mondino PJ, Azevedo ML, Santos KR, GiambiaquideMarval MM. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. *Eur J Clin Microbiol Infect Dis* 1999; **18**: 393–398.
- 637 Centers for Disease Control. *Vancomycin-intermediate/resistant Staphylococcus aureus laboratory testing algorithm* 2006 26 February 2009, p 1.
- 638 Centers for Disease Control and Prevention (CDC). Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep* 1995; **22**(44(RR-12)): 1–13.
- 639 NCCLS. Performance standards for antimicrobial disk susceptibility testing. Fourteenth informational supplement. NCCLS document 2004, M100–M514.
- 640 Waris T. Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. *MMWR Morb Mortal Wkly Rep* 1997; **46**: 813–815.
- 641 Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B *et al.* Emergence of vancomycin resistance in Staphylococcus aureus. *N Engl J Med* 1999; **340**: 493–501.
- 642 Centers for Disease Control and Prevention. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. *MMWR Morb Mortal Wkly Rep* 1997; **46**: 626–628.
- 643 Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin—United States, 2002. *MMWR Morb Mortal Wkly Rep* 2002; **51**: 565–567.
- 644 Waldvogel FA. New resistance in Staphylococcus aureus. *N Engl J Med* 1999; **340**: 556–557.
- 645 Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP *et al.* Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007; **44**: 159–177.
- 646 Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S *et al.* Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. *Bone Marrow Transplant* 2005; **35**: 497–499.
- 647 Dubberke ER, Hollands JM, Georgantopoulos P, Augustin K, DiPersio JF, Mundy LM *et al.* Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? *Bone Marrow Transplant* 2006; **38**: 813–819.
- 648 Montecalvo MA, Shay DK, Patel P, Tacsas L, Maloney SA, Jarvis WR *et al.* Bloodstream infections with vancomycin-resistant enterococci. *Arch Intern Med* 1996; **156**: 1458–1462.
- 649 Kirkpatrick BD, Harrington SM, Smith D, Marcellus D, Miller C, Dick J *et al.* An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. *Clin Infect Dis* 1999; **29**: 1268–1273.
- 650 Donskey CJ, Chowdhry TK, Hecker MT, Huyen CK, Hanrahan JA, Hujer AM *et al.* Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. *N Engl J Med* 2000; **343**: 1925–1932.
- 651 Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007; **45**: 302–307.

References

- 652 Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K *et al.* Natural history of colonization with vancomycin-resistant *Enterococcus faecium*. *Infect Control Hosp Epidemiol* 1995; **16**: 680–685.
- 653 Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS *et al.* Prolonged colonization with vancomycin-resistant *Enterococcus faecium* in long-term care patients and the significance of ‘clearance’. *Clin Infect Dis* 2001; **33**: 1654–1660.
- 654 Donskey CJ, Hoyer CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant *Enterococcus* stool colonization during antibiotic therapy. *Infect Control Hosp Epidemiol* 2002; **23**: 436–440.
- 655 Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C *et al.* Controlling vancomycin-resistant enterococci. *Infect Control Hosp Epidemiol* 1995; **16**: 634–637.
- 656 Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J *et al.* Epidemiology and successful control of a large outbreak due to *Klebsiella pneumoniae* producing extended-spectrum beta-lactamases. *Antimicrob Agents Chemother* 1998; **42**: 53–58.
- 657 Troche G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. *Infect Control Hosp Epidemiol* 2005; **26**: 161–165.
- 658 Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J *et al.* Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. *Clin Infect Dis* 2007; **45**: 846–852.
- 659 Gardam MA, Burrows LL, Kus JV, Brunton J, Low DE, Conly JM *et al.* Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? *J Infect Dis* 2002; **186**: 1754–1760.
- 660 Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. *MMWR Morb Mortal Wkly Rep* 2009; **58**: 256–260.
- 661 Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva Jr J. *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* 1995; **16**: 459–477.
- 662 Johnson S, Gerding DN. *Clostridium difficile*—associated diarrhea. *Clin Infect Dis* 1998; **26**: 1027–1034; quiz 1035–1036.
- 663 McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med* 1989; **320**: 204–210.
- 664 Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Clabots CR *et al.* Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* 1990; **88**: 137–140.
- 665 Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. *Clostridium difficile* skin contamination in patients with *C. difficile*-associated disease. *Clin Infect Dis* 2008; **46**: 447–450.
- 666 Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR *et al.* Treatment of asymptomatic *Clostridium difficile* carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Ann Intern Med* 1992; **117**: 297–302.
- 667 Boyce JM, Ligi C, Kohan C, Dumigan D, Havill NL. Lack of association between the increased incidence of *Clostridium difficile*-associated disease and the increasing use of alcohol-based hand rubs. *Infect Control Hosp Epidemiol* 2006; **27**: 479–483.
- 668 Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove *Bacillus atrophaceus* (a surrogate of *Bacillus anthracis*) from contaminated hands. *JAMA* 2003; **289**: 1274–1277.
- 669 Perez J, Springthorpe VS, Sattar SA. Activity of selected oxidizing microbicides against the spores of *Clostridium difficile*: relevance to environmental control. *Am J Infect Control* 2005; **33**: 320–325.
- 670 Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of *Clostridium difficile*. *Clin Infect Dis* 2000; **31**: 995–1000.
- 671 Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. *Biol Blood Marrow Transplant* 2001; **7**(Suppl): 19S–22S.
- 672 Whimby E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. *Am J Med* 1997; **102**(3A): 10–18; discussion 25–26.
- 673 Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA *et al.* An outbreak of respiratory syncytial virus in a bone marrow transplant center. *J Infect Dis* 1992; **165**: 987–993.
- 674 Fox JP, Brandt CD, Wassermann FE, Hall CE, Spigland I, Kogon A *et al.* The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VI. Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. *Am J Epidemiol* 1969; **89**: 25–50.
- 675 Hillis WO, Cooper MR, Bang FB. Adenovirus infection in West Bengal. I: persistence of viruses in infants and young children. *Indian J Med Res* 1973; **61**: 980–988.
- 676 Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC *et al.* Respiratory syncytial viral infection in children with compromised immune function. *N Engl J Med* 1986; **315**: 77–81.
- 677 Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2003; **32**: 1085–1088.
- 678 Madge P, Paton JY, McColl JH, Mackie PL. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. *Lancet* 1992; **340**: 1079–1083.
- 679 Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L *et al.* Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. *Clin Infect Dis* 2007; **45**: 187–193.
- 680 Jalal H, Bibby DF, Tang JW, Bennett J, Kyriakou C, Peggs K *et al.* First reported outbreak of diarrhea due to adenovirus infection in a hematology unit for adults. *J Clin Microbiol* 2005; **43**: 2575–2580.
- 681 Musher DM. How contagious are common respiratory tract infections? *N Engl J Med* 2003; **348**: 1256–1266.
- 682 Nauheim RC, Romanowski EG, Araullo-Cruz T, Kowalski RP, Turgeon PW, Stopak SS *et al.* Prolonged recoverability of desiccated adenovirus type 19 from various surfaces. *Ophthalmology* 1990; **97**: 1450–1453.
- 683 Gordon YJ, Gordon RY, Romanowski E, Araullo-Cruz TP. Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces *in vitro*. *Ophthalmology* 1993; **100**: 1835–1839; discussion 1839–1840.
- 684 Mahl MC, Sadler C. Virus survival on inanimate surfaces. *Can J Microbiol* 1975; **21**: 819–823.
- 685 Sattar SA, Abebe M, Bueti AJ, Jampani H, Newman J, Hua S. Activity of an alcohol-based hand gel against human adenovirus, rhinovirus, and rotaviruses using the fingerpad method. *Infect Control Hosp Epidemiol* 2000; **21**: 516–519.
- 686 Rutala WA, Peacock JE, Gergen MF, Sobsey MD, Weber DJ. Efficacy of hospital germicides against adenovirus 8, a common cause of epidemic keratoconjunctivitis in health care facilities. *Antimicrob Agents Chemother* 2006; **50**: 1419–1424.
- 687 Butz AM, Fosarelli P, Dick J, Cusack T, Yolken R. Prevalence of rotavirus on high-risk fomites in day-care facilities. *Pediatrics* 1993; **92**: 202–205.
- 688 Sattar SA, Lloyd-Evans N, Springthorpe VS, Nair RC. Institutional outbreaks of rotavirus diarrhoea: potential role of fomites and environmental surfaces as vehicles for virus transmission. *J Hyg (Lond)* 1986; **96**: 277–289.
- 689 Gallimore CI, Taylor C, Gennery AR, Cant AJ, Galloway A, Iturriza-Gomara M *et al.* Environmental monitoring for gastroenteric viruses in a pediatric primary immunodeficiency unit. *J Clin Microbiol* 2006; **44**: 395–399.
- 690 Ansari SA, Sattar SA, Springthorpe VS, Wells GA, Tostowaryk W. Rotavirus survival on human hands and transfer of infectious virus to animate and nonporous inanimate surfaces. *J Clin Microbiol* 1988; **26**: 1513–1518.
- 691 Lages SL, Ramakrishnan MA, Goyal SM. *In-vivo* efficacy of hand sanitisers against feline calicivirus: a surrogate for norovirus. *J Hosp Infect* 2008; **68**: 159–163.
- 692 Kampf G, Grothier D, Steinmann J. Efficacy of three ethanol-based hand rubs against feline calicivirus, a surrogate virus for norovirus. *J Hosp Infect* 2005; **60**: 144–149.
- 693 Gehrke C, Steinmann J, Goroncy-Bernes P. Inactivation of feline calicivirus, a surrogate of norovirus (formerly Norwalk-like viruses), by different types of alcohol *in vitro* and *in vivo*. *J Hosp Infect* 2004; **56**: 49–55.

- 694 Duizer E, Bijkerk P, Rockx B, De Groot A, Twisk F, Koopmans M. Inactivation of caliciviruses. *Appl Environ Microbiol* 2004; **70**: 4538–4543.
- 695 Centers for Disease Control and Prevention (CDC). *Norovirus in Healthcare Facilities Fact Sheet*. National Center for Preparedness, Detection, and Control of Infectious Diseases: Atlanta, GA, 2006.
- 696 Gallimore CI, Taylor C, Gennery AR, Cant AJ, Galloway A, Lewis D *et al*. Use of a heminested reverse transcriptase PCR assay for detection of astrovirus in environmental swabs from an outbreak of gastroenteritis in a pediatric primary immunodeficiency unit. *J Clin Microbiol* 2005; **43**: 3890–3894.
- 697 Marshall JA, Bruggink LD, Sturge K, Subasinghe N, Tan A, Hogg GG. Molecular features of astrovirus associated with a gastroenteritis outbreak in an aged-care centre. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 67–71.
- 698 Glass RI, Noel J, Mitchell D, Herrmann JE, Blacklow NR, Pickering LK *et al*. The changing epidemiology of astrovirus-associated gastroenteritis: a review. *Arch Virol Suppl* 1996; **12**: 287–300.
- 699 Sebire NJ, Malone M, Shah N, Anderson G, Gaspar HB, Cubitt WD. Pathology of astrovirus associated diarrhoea in a paediatric bone marrow transplant recipient. *J Clin Pathol* 2004; **57**: 1001–1003.
- 700 LeBaron CW, Furutan NP, Lew JF, Allen JR, Gouvea V, Moe C *et al*. Viral agents of gastroenteritis. Public health importance and outbreak management. *MMWR Recomm Rep* 1990; **39**(RR-5): 1–24.
- 701 Gaynes RP, Horan TC. Surveillance of nosocomial infections. In: CG Mayhall (ed). *Hospital Epidemiology and Infection Control*, 2nd edn. Lippincott Williams & Wilkins: Philadelphia, PA, 1999, pp 1285–317-85.
- 702 De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T *et al*. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008; **46**: 1813–1821.
- 703 Lee GM, Salomon JA, Friedman JF, Hibberd PL, Ross-Degnan D, Zasloff E *et al*. Illness transmission in the home: a possible role for alcohol-based hand gels. *Pediatrics* 2005; **115**: 852–860.
- 704 Sandora TJ, Taveras EM, Shih MC, Resnick EA, Lee GM, Ross-Degnan D *et al*. A randomized, controlled trial of a multifaceted intervention including alcohol-based hand sanitizer and hand-hygiene education to reduce illness transmission in the home. *Pediatrics* 2005; **116**: 587–594.
- 705 Centers for Disease Control and Prevention. *Preventing Cryptosporidiosis: A Guide for People with Compromised Immune System* 2005.
- 706 Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. *Ann Intern Med* 2002; **137**(Part 2): 435–478.
- 707 Kerr LN, Chaput MP, Cash LD, O'Malley LG, Sarhrani EM, Teixeira JC *et al*. Assessment of the durability of medical examination gloves. *J Occup Environ Hyg* 2004; **1**: 607–612.
- 708 Korniewicz DM, El-Masri M, Broyles JM, Martin CD, O'Connell KP. Performance of latex and nonlatex medical examination gloves during simulated use. *Am J Infect Control* 2002; **30**: 133–138.
- 709 Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. *Semin Respir Crit Care Med* 2007; **28**: 222–242.
- 710 Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altamirano A *et al*. Effect of handwashing on child health: a randomised controlled trial. *Lancet* 2005; **366**: 225–233.
- 711 Roberts L, Smith W, Jorm L, Patel M, Douglas RM, McGilchrist C. Effect of infection control measures on the frequency of upper respiratory infection in child care: a randomized, controlled trial. *Pediatrics* 2000; **105**(Part 1): 738–742.
- 712 Ryan MA, Christian RS, Wohlrahe J. Handwashing and respiratory illness among young adults in military training. *Am J Prev Med* 2001; **21**: 79–83.
- 713 White C, Kolble R, Carlson R, Lipson N, Dolan M, Ali Y *et al*. The effect of hand hygiene on illness rate among students in university residence halls. *Am J Infect Control* 2003; **31**: 364–370.
- 714 Lau JT, Tsui H, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. *Emerg Infect Dis* 2004; **10**: 587–592.
- 715 Chatterjee A, Plummer S, Heybrock B, Bardon T, Eischen K, Hall M *et al*. A modified 'cover your cough' campaign prevents exposures of employees to pertussis at a children's hospital. *Am J Infect Control* 2007; **35**: 489–491.
- 716 Centers for Disease Control and Prevention. Legionnaires' Disease associated with potting soil—California, Oregon, and Washington, May–June 2000. *MMWR Morb Mortal Wkly Rep* 2000; **49**: 777–778.
- 717 Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. *MMWR Recomm Rep* 2000; **49**(RR-2): 59–68.
- 718 O'Connor BA, Carman J, Eckert K, Tucker G, Givney R, Cameron S. Does using potting mix make you sick? Results from a Legionella longbeachae case-control study in South Australia. *Epidemiol Infect* 2007; **135**: 34–39.
- 719 De Groote MA, Pace NR, Fulton K, Falkinham III JO. Relationships between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils. *Appl Environ Microbiol* 2006; **72**: 7602–7606.
- 720 Wilson M, Robson J, Pyke CM, McCormack JG. Saksenaeva vasiformis breast abscess related to gardening injury. *Aust N Z J Med* 1998; **28**: 845–846.
- 721 Golledge C. An infection from a penetrating plant wound. *Aust Fam Physician* 1995; **24**: 2099.
- 722 Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H *et al*. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. *Clin Infect Dis* 2007; **45**: 673–681.
- 723 Stark D, Milliken S, Marriott D, Harkness J. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. *J Med Microbiol* 2007; **56**(Part 5): 699–701.
- 724 Praz-Christinaz SM, Lazor-Blanchet C, Binet I, Boillat MA, Danuser B. Occupational risk assessment of aspergillosis after renal transplantation. *Transpl Infect Dis* 2007; **9**: 175–181.
- 725 Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. *Med Mycol* 2005; **43**: 705–710.
- 726 Blair JE. Coccidioidomycosis in patients who have undergone transplantation. *Ann N Y Acad Sci* 2007; **1111**: 365–376.
- 727 Centers for Disease Control and Prevention. Increase in coccidioidomycosis—Arizona, 1998–2001. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 109–112.
- 728 Lyon GM, Bravo AV, Espino A, Lindsley MD, Gutierrez RE, Rodriguez I *et al*. Histoplasmosis associated with exploring a bat-inhabited cave in Costa Rica, 1998–1999. *Am J Trop Med Hyg* 2004; **70**: 438–442.
- 729 Huhn GD, Austin C, Carr M, Heyer D, Boudreau P, Gilbert G *et al*. Two outbreaks of occupationally acquired histoplasmosis: more than workers at risk. *Environ Health Perspect* 2005; **113**: 585–589.
- 730 Centers for Disease Control and Prevention. Outbreak of histoplasmosis among industrial plant workers—Nebraska, 2004. *MMWR Morb Mortal Wkly Rep* 2004; **53**: 1020–1022.
- 731 Jie T, Matas AJ, Gillingham KJ, Sutherland DE, Dunn DL, Humar A. Mycobacterial infections after kidney transplant. *Transplant Proc* 2005; **37**: 937–939.
- 732 Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. *MMWR Recomm Rep* 2006; **55** (RR-9): 1–44.
- 733 Lavoie J, Dunkerley CJ, Kosatsky T, Dufresne A. Exposure to aerosolized bacteria and fungi among collectors of commercial, mixed residential, recyclable and compostable waste. *Sci Total Environ* 2006; **370**: 23–28.
- 734 Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2000; **49**(RR-5): 1–22; quiz CE1–7.
- 735 Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2006; **55**(RR-12): 1–13.

- 736 Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpaa R, Salmi A *et al.* A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. *Pediatr Infect Dis J* 2006; **25**: 590–595.
- 737 Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio P, Gabbay YB *et al.* Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. *J Pediatr (Rio J)* 2007; **83**: 217–224.
- 738 Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC *et al.* Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N Engl J Med* 2006; **354**: 11–22.
- 739 Clinical Review for STN 125265/0 Rotarix 2008.
- 740 Ali T, Scott N, Kallas W, Halliwell ME, Savino C, Rosenberg E *et al.* Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). *Clin Infect Dis* 2004; **38**: 760–762.
- 741 Talbot TR, Crocker DD, Peters J, Doersam JK, Ikizler MR, Sannella E *et al.* Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. *Infect Control Hosp Epidemiol* 2005; **26**: 494–500.
- 742 Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. *J Clin Microbiol* 2000; **38**: 839–845.
- 743 Buonagurio DA, O'Neill RE, Shutyak L, D'Arco GA, Bechert TM, Kazachkov Y *et al.* Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. *Virology* 2006; **347**: 296–306.
- 744 ACIP Provisional Recommendations for use of Zoster Vaccine 2008 (April 22).
- 745 Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S *et al.* Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. *Pediatrics* 1991; **87**: 166–170.
- 746 Centers for Disease Control and Prevention (CDC). 'Crypto'—*Cryptosporidiosis: Prevention—Immunocompromised Persons* 2008; 2008(July 21).
- 747 Angulo FJ, Glaser CA, Juranek DD, Lappin MR, Regnery RL. Caring for pets of immunocompromised persons. *J Am Vet Med Assoc* 1994; **205**: 1711–1718.
- 748 Elliot DL, Tolle SW, Goldberg L, Miller JB. Pet-associated illness. *N Engl J Med* 1985; **313**: 985–995.
- 749 Glaser CA, Angulo FJ, Rooney JA. Animal-associated opportunistic infections among persons infected with the human immunodeficiency virus. *Clin Infect Dis* 1994; **18**: 14–24.
- 750 Dalton C, Hoffman R, Pape J. Iguana-associated salmonellosis in children. *Pediatr Infect Dis J* 1995; **14**: 319–320.
- 751 Centers for Disease Control and Prevention (CDC). Reptile-associated salmonellosis—selected states, 1998–2002. *MMWR Morb Mortal Wkly Rep* 2003; **52**: 1206–1209.
- 752 Mermin J, Hoar B, Angulo FJ. Iguanas and *Salmonella marina* infection in children: a reflection of the increasing incidence of reptile-associated salmonellosis in the United States. *Pediatrics* 1997; **99**: 399–402.
- 753 Centers for Disease Control and Prevention (CDC). Salmonellosis associated with chicks and ducklings—Michigan and Missouri, Spring 1999. *MMWR Morb Mortal Wkly Rep* 2000; **49**: 297–299.
- 754 Adams RM. Animals in schools: a zoonosis threat? *Pediatr Infect Dis J* 1998; **17**: 174–176.
- 755 Berkelman RL. Human illness associated with use of veterinary vaccines. *Clin Infect Dis* 2003; **37**: 407–414.
- 756 DiSalvo H, Haiduvan D, Johnson N, Reyes VV, Hench CP, Shaw R *et al.* Who let the dogs out? Infection control did: utility of dogs in health care settings and infection control aspects. *Am J Infect Control* 2006; **34**: 301–307.
- 757 Centers for Disease Control and Prevention (CDC). Lake-associated outbreak of *Escherichia coli* O157:H7—Illinois, 1995. *MMWR Morb Mortal Wkly Rep* 1996; **45**: 437–439.
- 758 Centers for Disease Control and Prevention (CDC). Outbreak of cryptosporidiosis associated with a water sprinkler fountain—Minnesota, 1997. *MMWR Morb Mortal Wkly Rep* 1998; **47**: 856–860.
- 759 Kramer MH, Sorhage FE, Goldstein ST, Dalley E, Wahlquist SP, Herwaldt BL. First reported outbreak in the United States of cryptosporidiosis associated with a recreational lake. *Clin Infect Dis* 1998; **26**: 27–33.
- 760 Centers for Disease Control and Prevention (CDC). *Risks from Food and Water (Drinking and Recreational)*. Centers for Disease Control and Prevention: Atlanta, Georgia, 2008.
- 761 van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinje J, Koopmans MP *et al.* Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. *Bone Marrow Transplant* 2000; **26**: 299–303.
- 762 American Academy of Pediatrics. Cryptosporidiosis. In: Pickering LK (ed). *Red Book: 2003 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2003, pp 123–127.
- 763 American Public Health Association. *Cryptosporidiosis. Control of Communicable Disease Manual*, 18th edn. American Public Health Association: Washington, DC, 2004, pp 138–141.
- 764 Keene WE, Hedberg K, Herriott DE, Hancock DD, McKay RW, Barrett TJ *et al.* A prolonged outbreak of *Escherichia coli* O157:H7 infections caused by commercially distributed raw milk. *J Infect Dis* 1997; **176**: 815–818.
- 765 Shen MW. Diagnostic and therapeutic challenges of childhood brucellosis in a nonendemic country. *Pediatrics* 2008; **121**: e1178–e1183.
- 766 Vojdani JD, Beuchat LR, Tauxe RV. Juice-associated outbreaks of human illness in the United States, 1995 through 2005. *J Food Prot* 2008; **71**: 356–364.
- 767 Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S *et al.* Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol* 2008; **26**: 5684–5688.
- 768 Handle and Prepare Food Safely 2008.
- 769 Todd EC. Epidemiology of foodborne diseases: a worldwide review. *World Health Stat Q* 1997; **50**: 30–50.
- 770 The Big Thaw—Safe Defrosting Methods for Consumers 2008.
- 771 Moe GL. Low-microbial diets for patients with granulocytopenia. In: Bloch AS (ed). *Nutrition Management of the Cancer Patient*. Aspen Publishing, Inc.: Rockville, MD, 1990, pp 125–134; 12.
- 772 Aker SN, Lensen P. Nutritional support of patients with hematologic malignancies. In: Benz Jr EJ, Cohen JJ, Burie B (eds). *Hematology: Basic Principles and Practice*, 3rd edn. Churchill Livingstone: New York, NY, 2000, pp 1501–1514; 80.
- 773 Moody K, Charlson ME, Finlay J. The neutropenic diet: what's the evidence? *J Pediatr Hematol Oncol* 2002; **24**: 717–721.
- 774 Centers for Disease Control and Prevention (CDC). Outbreaks of *Salmonella* serotype enteritidis infection associated with eating shell eggs—United States, 1999–2001. *MMWR Morb Mortal Wkly Rep* 2003; **51**: 1149–1152.
- 775 Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. *Lancet Infect Dis* 2006; **6**: 374–382.
- 776 Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. *Clin Microbiol Infect* 2007; **13**: 657–664.
- 777 Antony SJ, Stratton CW, Dummer JS. *Lactobacillus* bacteremia: description of the clinical course in adult patients without endocarditis. *Clin Infect Dis* 1996; **23**: 773–778.
- 778 Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. *Clin Infect Dis* 1996; **22**: 521–524.
- 779 Centers for Disease Control and Prevention (CDC). *Travelers' Health: Destinations*. Centers for Disease Control and Prevention: Atlanta, Georgia, 2007.
- 780 Centers for Disease Control and Prevention (CDC). Outbreak of acute febrile illness among athletes participating in triathlons—Wisconsin and Illinois, 1998. *MMWR Morb Mortal Wkly Rep* 1998; **47**: 585–588.
- 781 Centers for Disease Control and Prevention (CDC). Outbreak of leptospirosis among white-water rafters—Costa Rica, 1996. *MMWR Morb Mortal Wkly Rep* 1997; **46**: 577–579.
- 782 Sejvar J, Bancroft E, Winthrop K, Bettinger J, Bajani M, Bragg S *et al.* Leptospirosis in 'Eco-Challenge' athletes, Malaysian Borneo, 2000. *Emerg Infect Dis* 2003; **9**: 702–707.
- 783 Leder K, Newman D. Respiratory infections during air travel. *Intern Med J* 2005; **35**: 50–55.
- 784 Centers for Disease Control and Prevention (CDC). *Travelers' Health: Yellow Book*. Centers for Disease Control and Prevention: Atlanta, Georgia, 2008.

- 785 Centers for Disease Control and Prevention (CDC). *Water Treatment Methods*. Centers for Disease Control and Prevention: Atlanta, GA.
- 786 Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J *et al*. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* 1995; **15**: 455–460.
- 787 Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R *et al*. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. *Bone Marrow Transplant* 2005; **35**: 737–746.
- 788 Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G *et al*. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. *J Infect Dis* 1989; **159**: 610–615.
- 789 Ljungman P, Wiklund HM, Duraj V, Hammarström L, Lönnqvist B, Paulin T *et al*. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. *J Infect Dis* 1990; **162**: 496–500.
- 790 Pauksen K, Duraj V, Ljungman P, Sjölin J, Öberg G, Lönnholm G *et al*. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. *Bone Marrow Transplant* 1992; **9**: 427–432.
- 791 Pauksen K, Hammarström V, Ljungman P, Sjölin J, Öberg G, Lönnholm G *et al*. Immunity to poliovirus and immunization with inactivated poliovaccine after autologous bone marrow transplantation. *Clin Infect Dis* 1994; **18**: 547–552.
- 792 Guinan EC, Molrine DC, Antin JH, Lee MC, Weinstein HJ, Sallan SE *et al*. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. *Transplantation* 1994; **57**: 677–684.
- 793 Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. *Streptococcus pneumoniae* infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. *Medicine* 2007; **86**: 69–77.
- 794 Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. *J Infect Dis* 1985; **152**: 1172–1181.
- 795 Nakano T, Shimono Y, Sugiyama K, Nishihara H, Higashigawa M, Komada Y *et al*. Clinical features of measles in immunocompromised children. *Acta Paediatr Jpn* 1996; **38**: 212–217.
- 796 Machado CM, Goncalves FB, Pannuti CS, Dullely FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. *Blood* 2002; **99**: 83–87.
- 797 Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA *et al*. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. *Clin Infect Dis* 2007; **45**: 1576–1582.
- 798 Machado CM. Influenza infections after hematopoietic stem cell transplantation. *Clin Infect Dis* 2005; **41**: 273–274.
- 799 Parkman R, Weinberg K. Immunological reconstitution following hematopoietic stem cell transplantation. In: Blume K, Forman S, Appelbaum F (eds). *Thomas's Hematopoietic Cell Transplantation*. Blackwell Science: Malden, 2003, pp 853–861.
- 800 Storek J, Witherspoon R. Immunological reconstitution after hematopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner M (eds). *Clinical Bone Marrow and Blood Stem Cell Transplantation*. Cambridge University Press: Cambridge, 2004, pp 194–226.
- 801 Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE *et al*. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. *Blood* 2004; **103**: 777–783.
- 802 Nordoy T, Husebekk A, Aaberge IS, Jennum PA, Samdal HH, Flugsrud LB *et al*. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. *Bone Marrow Transplant* 2001; **28**: 681–687.
- 803 Pauksen K, Linde A, Hammarström V, Sjölin J, Carneskog J, Jonsson G *et al*. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. *Clin Infect Dis* 2000; **30**: 342–348.
- 804 Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI *et al*. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. *Bone Marrow Transplant* 2001; **28**: 775–781.
- 805 van der Velden AM, Claessen AM, van Velzen-Blad H, Biesma DH, Rijkjer GT. Development of functional *Haemophilus influenzae* type b antibodies after vaccination. *Haematologica* 2005; **90**: 1582–1584.
- 806 Meisel R, Kuypers L, Dirksen U, Schubert R, Gruhn B, Strauss G *et al*. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. *Blood* 2007; **109**: 2322–2326.
- 807 Molrine DC, Antin JH, Guinan EC, Soiffer RJ, MacDonald K, Malley R *et al*. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. *Blood* 2003; **101**: 831–836.
- 808 Cordonnier C, Labopin M, Chesnel V, Ribaud P, de la Camara R, Martino R *et al*. Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial. *Blood* 2008; **112**: 350.
- 809 Papadopoulos EB, Young JW, Kernan NA, Bould F, Castro-Malaspina HR, O'Reilly RJ *et al*. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients [abstract]. *Blood* 2008; **112**: 2214.
- 810 Small TN, Zelenetz AD, Noy A, Rice RD, Trippett TM, Abrey L *et al*. Pertussis Immunity and Response to tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) following autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* (in press).
- 811 Parkkali T, Kayhty H, Lehtonen H, Ruutu T, Volin L, Eskola J *et al*. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. *Bone Marrow Transplant* 2001; **27**: 79–84.
- 812 Mahler M, Kernan NA, Bould F, Prockop S, Scaradavou A, Papadopoulos EB *et al*. Immunogenicity of the tetravalent protein-conjugated meningococcal vaccine in recipients of related and unrelated allogeneic hematopoietic cell transplants (HCT) [abstract]. *Blood* 2008; **112**: 1163.
- 813 Geddes M, Storek J. Immune reconstitution following hematopoietic stem-cell transplantation. *Best Pract Res Clin Haematol* 2007; **20**: 329–348.
- 814 Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB *et al*. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. *Bone Marrow Transplant* 2006; **37**: 865–871.
- 815 Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L *et al*. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2007; **13**: 1216–1223.
- 816 Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS *et al*. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood* 2006; **107**: 1688–1695.
- 817 Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB *et al*. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *Blood* 2004; **104**: 2254–2262.
- 818 Storek J, Espino G, Dawson MA, Storer B, Flowers MED, Maloney DG. Low B cell and monocyte counts on day 80 are associated with high infection rates between day 100 and 365 after allogeneic marrow transplantation. *Blood* 2000; **96**: 3290–3293.
- 819 Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. *Transplantation* 2002; **74**: 1551–1559.
- 820 Boeckh M, Nakamura R, Cornelissen J. Immune monitoring with iTAG (TM) MHC tetramers for prediction of recurrent or persistent CMV infection in allogeneic stem cell transplant recipients: a prospective multicenter clinical trial. *Biol Blood Marrow Transplant* 2006; **12**(Suppl 1): 79.
- 821 Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA *et al*. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin

- lymphoma: a prospective study. *Biol Blood Marrow Transplant* 2008; **14**: 807–816.
- 822 Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. *Biol Blood Marrow Transplant* 2008; **14**: 323–334.
- 823 Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A *et al*. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. *Blood* 2002; **100**: 3908–3918.
- 824 Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H *et al*. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. *Blood* 2006; **107**: 4189–4193.
- 825 Dickinson AM. Risk assessment in haematopoietic stem cell transplantation: pre-transplant patient and donor factors: non-HLA genetics. *Best Pract Res Clin Haematol* 2007; **20**: 189–207.
- 826 Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M *et al*. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. *N Engl J Med* 2008; **359**: 1766–1777.
- 827 Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlerdacha B, Guerra M *et al*. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. *MMWR Recomm Rep* 2008; **57**(RR-3): 1–28.
- 828 American Academy of Pediatrics. Rabies. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 552–559.
- 829 Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2006; **55**(RR-7): 1–23.
- 830 Monto AS, Robinson DP, Herlocher ML, Hinson Jr JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA* 1999; **282**: 31–35.
- 831 Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D *et al*. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med* 1999; **341**: 1336–1343.
- 832 Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2000; **49**(RR-5): 1–22; quiz CE1–7.
- 833 American Academy of Pediatrics. Poliovirus Infections. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 542–547.
- 834 Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. *N Engl J Med* 1986; **314**: 560–564.
- 835 Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. *Pediatr Infect Dis J* 1997; **16**: 696–707.
- 836 American Academy of Pediatrics. Passive Immunization. In: LK Pickering (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 54–55.
- 837 Abe S, Miyamura K, Oba T, Terakura S, Kasai M, Kitaori K *et al*. Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. *Bone Marrow Transplant* 2003; **32**: 1107–1108.
- 838 Cheng WT, Li CK, Leung TF, Li AM, Hon KL, Ng PC *et al*. Ribavirin for SARS in children. *Clin Pediatr (Phila)* 2004; **43**: 193–196.
- 839 Naquira C, Jimenez G, Guerra JG, Bernal R, Nalin DR, Neu D *et al*. Ivermectin for human strongyloidiasis and other intestinal helminths. *Am J Trop Med Hyg* 1989; **40**: 304–309.
- 840 Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. *N Engl J Med* 1999; **340**: 1377–1382.
- 841 Centers for Disease Control and Prevention (CDC). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1998; **47**(RR-20): 1–58.
- 842 American Academy of Pediatrics. Tuberculosis. In: Pickering LK (ed). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 26th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006, pp 678–698.